

CITATION REPORT

List of articles citing

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

DOI: 10.1056/nejmoa2012410

New England Journal of Medicine, 2020, 382, 2411-2418.

Source: <https://exaly.com/paper-pdf/76622516/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1254	Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients. 2020 , 7, ofaa446		34
1253	Safety of intravenous anakinra in COVID-19 with evidence of hyperinflammation, a case series. 2020 , 4, rkaa040		7
1252	Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020). 2020 , 29,		50
1251	Immunomodulation for Severe COVID-19 Pneumonia: The State of the Art. 2020 , 11, 577442		16
1250	Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused. 2020 , 7, 539		12
1249	Clinical and cardiac characteristics of COVID-19 mortalities in a diverse New York City Cohort. 2020 , 31, 3086-3096		23
1248	Actualizaci3n de la Declaraci3n de consenso en medicina critica para la atenci3n multidisciplinaria del paciente con sospecha o confirmaci3n diagn3stica de COVID-19. 2020 , 20, 1-112		2
1247	COVID-19 therapies and their impact on QT interval prolongation: A multicentre retrospective study on 196 patients. 2020 , 30, 100637		3
1246	Factors associated with clinical outcomes in patients with Coronavirus Disease 2019 in Guangzhou, China. 2020 , 133, 104661		5
1245	The Potential Role of Coagulation Factor Xa in the Pathophysiology of COVID-19: A Role for Anticoagulants as Multimodal Therapeutic Agents. 2020 , 4, e288-e299		15
1244	SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies. 2020 , 13, 255-260		12
1243	Clinical management of Lupus patients during the COVID-19 pandemic. 2020 , 29, 1661-1672		7
1242	Coronavirus Historical Perspective, Disease Mechanisms, and Clinical Outcomes: JACC Focus Seminar. 2020 , 76, 1999-2010		13
1241	Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization. 2020 , 45, 703-713		7
1240	Repurposing anticancer drugs for the management of COVID-19. 2020 , 141, 40-61		30
1239	COVID-19 associated complications and potential therapeutic targets. 2020 , 886, 173548		10
1238	Interferon β 1b in treatment of severe COVID-19: A randomized clinical trial. 2020 , 88, 106903		82

1237	Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus. 2020 , 79, 153333	31
1236	Severe COVID-19: what have we learned with the immunopathogenesis?. 2020 , 60, 50	29
1235	Malaria and COVID-19: Common and Different Findings. 2020 , 5,	31
1234	No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials". 2020 , 14, 1673-1680	31
1233	An open-label, randomized trial of the combination of IFN- β plus TFF2 with standard care in the treatment of patients with moderate COVID-19. 2020 , 27, 100547	17
1232	SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for a Versatile Virus. 2020 , 11, 1224	17
1231	Risk Factors for Hospitalization, Mechanical Ventilation, or Death Among 10 131 US Veterans With SARS-CoV-2 Infection. 2020 , 3, e2022310	158
1230	Cytomegalovirus Enterocolitis secondary to experimental COVID-19 therapy. 2020 , 22, e00962	9
1229	Selenium and selenoproteins in viral infection with potential relevance to COVID-19. 2020 , 37, 101715	53
1228	Pandemic treatments on trial: the bigger picture.. 2020 , 56,	2
1227	Early management of critically ill patients with COVID-19. 2020 , 1, 1418-1426	0
1226	The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis. 2020 , 2020, 4312519	16
1225	Myotonic dystrophy type 1 as a major risk factor for severe COVID-19?. 2021 , 121, 1761-1765	4
1224	Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?. 2020 , 262, 118541	4
1223	[Renin-angiotensin system blockers and outcomes during hydroxychloroquine treatment in patients hospitalized for COVID-19 pneumonia]. 2020 , 73, 964-966	
1222	Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes. 2020 , 184, 104955	31
1221	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2020 , 383, 2030-2040	59.2 628
1220	Cardiac electrophysiology consultative experience at the epicenter of the COVID-19 pandemic in the United States. 2020 , 20, 250-256	10

1219	CURRENT THERAPEUTIC OPTIONS FOR CORONAVIRUS DISEASE-2019 – A PHARMACOLOGICAL REVIEW. 2020 , 42-50	
1218	A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: Results of a retrospective observational study in the French overseas department of R�union Island. 2020 , 23, 1-3	7
1217	COVID-19 disparities: An urgent call for race reporting and representation in clinical research. 2020 , 19, 100630	24
1216	Renin-angiotensin system blockers and outcomes during hydroxychloroquine treatment in patients hospitalized for COVID-19 pneumonia. 2020 , 73, 964-966	
1215	Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial. 2021 , 73, e4073-e4081	150
1214	Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality. 2020 , 40, 1072-1081	9
1213	Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena. 2020 , 11, 585888	7
1212	Chloroquine and hydroxychloroquine for combating COVID-19: Investigating efficacy and hypothesizing new formulations using Bio/chemoinformatics tools. 2020 , 21, 100446	11
1211	Virtual and Antiviral Screening Revive Therapeutic Drugs for COVID-19. 2020 , 3, 1278-1292	22
1210	Obesity and the Risk of Intubation or Death in Patients With Coronavirus Disease 2019. 2020 , 48, e1097-e1101	16
1209	Biomarkers of COVID-19 and technologies to combat SARS-CoV-2. 2020 , 2, 1-23	45
1208	SARS-CoV-2: From Structure to Pathology, Host Immune Response and Therapeutic Management. 2020 , 8,	3
1207	Management Considerations for the COVID-19 Patient with Severe Disease: a Case Scenario and Literature Review. 2020 , 1-7	1
1206	Territories Under Siege: Risks of the Decimation of Indigenous and Quilombolas Peoples in the Context of COVID-19 in South Brazil. 2021 , 8, 1119-1129	7
1205	Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants. 2020 , 56, 106144	76
1204	"Cytokine storm", not only in COVID-19 patients. Mini-review. 2020 , 228, 38-44	9
1203	Comparing the impact of Hydroxychloroquine based regimens and standard treatment on COVID-19 patient outcomes: A retrospective cohort study. 2020 , 28, 1877-1882	6
1202	Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review. 2020 , 38, 100776	20

1201	Combining hydroxychloroquine and minocycline: potential role in moderate to severe COVID-19 infection. 2020 , 13, 1183-1190	5
1200	Drug-induced 'Torsade de Pointes' in a COVID-19 patient despite discontinuation of chloroquine. Importance of its long half-life: a case report. 2020 , 4, 1-5	3
1199	[Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality]. 2020 , 155, 375-381	5
1198	COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. 2020 , 17, 543-558	560
1197	Pharmaco-Immunomodulatory Therapy in COVID-19. 2020 , 80, 1267-1292	128
1196	Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19. 2020 , 6, 2304-2318	25
1195	Recent Advancements in the Diagnosis, Prevention, and Prospective Drug Therapy of COVID-19. 2020 , 8, 384	7
1194	COVID-19 Pandemic in India: Present Scenario and a Steep Climb Ahead. 2020 , 11, 2150132720939402	23
1193	Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients. 2020 , 11, 1439	16
1192	Improving Clinical Trial Enrollment - In the Covid-19 Era and Beyond. <i>New England Journal of Medicine</i> , 2020 , 383, 1406-1408	59.2 27
1191	Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?. 2020 , 56, 106056	18
1190	Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. 2020 , 59, 176-190	44
1189	COVID-19 treatment: Much research and testing, but far, few magic bullets against SARS-CoV-2 coronavirus. 2020 , 203, 112647	17
1188	Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes. 2020 , 12, 895-908	50
1187	The Cardiovascular Effects of Treatment with Hydroxychloroquine and Azithromycin. 2020 , 40, 978-983	4
1186	Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. 2020 , 883, 173375	49
1185	Pathogenesis and management of myocardial injury in coronavirus disease 2019. 2020 , 22, 1994-2006	19
1184	Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection. 2020 , 108, 1135-1149	17

1183	Beyond the operating room: the roles of anaesthesiologists in pandemics. 2020 , 125, 444-447	2
1182	Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis. 2020 , 24, 418	36
1181	Pharmacist's perspective on HCQ treatment of COVID-19. 2020 , 36, 660	
1180	QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin. 2020 , 59, 337-345	17
1179	Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid). 2020 , 7, 572485	10
1178	Chloroquine, hydroxychloroquine, and COVID-19: Systematic review and narrative synthesis of efficacy and safety. 2020 , 28, 1760-1776	14
1177	Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. 2020 , 27, 434-441	2
1176	Repurposing Sigma-1 Receptor Ligands for COVID-19 Therapy?. 2020 , 11, 582310	39
1175	Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. 2020 , 1, 100146	13
1174	Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. 2020 , 29, 100645	34
1173	Interferon β_1a (IFN β_1a) in COVID-19 patients (INTERCOP): study protocol for a randomized controlled trial. 2020 , 21, 939	14
1172	Clinical characteristics and outcome of hospitalized patients with SARS-CoV-2 infection at Toulouse University hospital (France). Results from the Covid-clinic-Toul cohort. 2020 , 41, 732-740	7
1171	Neuromuscular Diseases Care in the Era of COVID-19. 2020 , 11, 588929	13
1170	Drug Repurposing Approaches to Combating Viral Infections. 2020 , 9,	9
1169	Recommendations for treatment of critically ill patients with COVID-19 : Version 3 S1 guideline. 2020 , 1	11
1168	Hydroxychloroquine use and COVID-19 concerns among alopecia patients: A cross-sectional survey study. 2020 , 33, e14529	
1167	Repurposing Anti-Cancer Drugs for COVID-19 Treatment. 2020 , 14, 5045-5058	14
1166	Recommendations for the Diagnosis, Prevention, and Control of Coronavirus Disease-19 in Children-The Chinese Perspectives. 2020 , 8, 553394	15

1165	Management of Pediatric Kidney Transplant Patients During the COVID-19 Pandemic: Guidance From the Canadian Society of Transplantation Pediatric Group. 2020 , 7, 2054358120967845	9
1164	Update Alert 2: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19. 2020 , 173, W128-W129	12
1163	Risk factors for mortality in hospitalized patients with COVID-19 at the start of the pandemic in Belgium: a retrospective cohort study. 2020 , 20, 897	23
1162	Lung transplantation for patients with severe COVID-19. 2020 , 12,	94
1161	Update Alert 3: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19. 2020 , 173, W156-W157	17
1160	Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians. 2020 , 173, W48-W51	8
1159	The Saga of Hydroxychloroquine and COVID-19: A Cautionary Tale. 2020 , 173, 662-663	7
1158	Association Between Ethnicity and Severe COVID-19 Disease: a Systematic Review and Meta-analysis. 2021 , 8, 1563-1572	19
1157	Is Machine Learning a Better Way to Identify COVID-19 Patients Who Might Benefit from Hydroxychloroquine Treatment?-The IDENTIFY Trial. 2020 , 9,	6
1156	Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality. 2020 , 155, 375-381	1
1155	Identification of an Antiviral Compound from the Pandemic Response Box that Efficiently Inhibits SARS-CoV-2 Infection In Vitro. 2020 , 8,	14
1154	Remdesivir Use in Patients Requiring Mechanical Ventilation due to COVID-19. 2020 , 7, ofaa481	12
1153	The "sex gap" in COVID-19 trials: a scoping review. 2020 , 29, 100652	21
1152	Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis. 2020 , 8,	4
1151	Update Alert: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19. 2020 , 173, W78-W79	15
1150	Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. 2020 , 173, 287-296	129
1149	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial. 2020 , 173, 623-631	298
1148	Side Effects of Chloroquine and Hydroxychloroquine on Skeletal Muscle: a Narrative Review. 2020 , 6, 1-9	10

1147	Cell Clearing Systems as Targets of Polyphenols in Viral Infections: Potential Implications for COVID-19 Pathogenesis. 2020 , 9,	18
1146	COVID-19 and Systemic Lupus Erythematosus: Focus on Immune Response and Therapeutics. 2020 , 11, 589474	25
1145	The COVID-19 pandemic: A community approach. 2020 , 34, e14059	7
1144	COVID-19 and immunological regulations - from basic and translational aspects to clinical implications. 2020 , 18, 795-807	25
1143	COVID-19: A review of the proposed pharmacological treatments. 2020 , 886, 173451	54
1142	Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments. 2020 , 88, 106885	20
1141	Severe arterial thromboembolism in patients with Covid-19. 2020 , 60, 106-110	4
1140	Hydroxychloroquine use in hospitalised patients with COVID-19: An observational matched cohort study. 2020 , 22, 842-844	11
1139	COVID-19: Pharmacology and kinetics of viral clearance. 2020 , 161, 105114	11
1138	Pathogenesis of SARS-CoV-2 induced cardiac injury from the perspective of the virus. 2020 , 147, 12-17	19
1137	Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges. 2020 , 13, 957-975	5
1136	Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019: Friend or Foe?. 2020 , 28, 266-271	8
1135	Covid-19 pandemic and pregnancy. 2020 , 46, 1958-1966	15
1134	Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis. 2020 ,	6
1133	Correspondence on ': hydroxychloroquine, COVID-19 and the role of the rheumatologist' by Graef. 2020 ,	4
1132	COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. 2020 , 1, 234-243	29
1131	Deploying Randomized Controlled Trials during the COVID-19 Pandemic: Reason and Bayesian Designs. 2020 , 17, 937-938	3
1130	Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock. 2020 , 18, 2689-2700	38

1129	Genetic Polymorphisms Complicate COVID-19 Therapy: Pivotal Role of HO-1 in Cytokine Storm. 2020 , 9,	26
1128	A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial. 2020 , 35, 725-733	20
1127	Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease. 2020 , 15, e0236778	14
1126	Insight into the pediatric and adult dichotomy of COVID-19: Age-related differences in the immune response to SARS-CoV-2 infection. 2020 , 55, 2556-2564	25
1125	Using "old" medications to fight new COVID-19: Re-purposing with a purpose. 2020 , 146, 41-42	1
1124	The Course of Mild and Moderate COVID-19 Infections-The Unexpected Long-Lasting Challenge. 2020 , 7, ofaa286	9
1123	COVID-19: A Perspective from Clinical Neurology and Neuroscience. 2020 , 26, 387-391	10
1122	HRS/EHRA/APHRS/LAHRs/ACC/AHA Worldwide Practice Update for Telehealth and Arrhythmia Monitoring During and After a Pandemic. 2020 , 13, e009007	6
1121	Acute chloroquine and hydroxychloroquine toxicity: A review for emergency clinicians. 2020 , 38, 2209-2217	21
1120	Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. <i>New England Journal of Medicine</i> , 2020 , 383, 2041-2052	59.2 620
1119	High doses of hydroxychloroquine do not affect viral clearance in patients with SARS-CoV-2 infection. 2020 , 50, e13358	2
1118	Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine. 2020 , 11, 1409	27
1117	Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019. 2020 , 2, 100159	22
1116	Early administration of interleukin-6 inhibitors for patients with severe COVID-19 disease is associated with decreased intubation, reduced mortality, and increased discharge. 2020 , 99, 28-33	40
1115	Canakinumab in a subgroup of patients with COVID-19. 2020 , 2, e457-ee458	72
1114	Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials. 2020 , 21,	27
1113	Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients. 2020 , 26, 1983-1994	26
1112	The Lord of the NanoRings: Cyclodextrins and the battle against SARS-CoV-2. 2020 , 588, 119689	24

1111	COVID-19 and the Kidneys: An Update. 2020 , 7, 423	48
1110	Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis. 2020 , 7, 482	22
1109	Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. 2020 , 59, 1195-1216	18
1108	In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. 2020 , 56, 106119	24
1107	Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients. 2020 , 14, 3001-3013	15
1106	Clarifying the record on hydroxychloroquine for the treatment of patients hospitalized with COVID-19. 2020 , 99, 38-39	3
1105	Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal?. 2020 , 99, 75-76	8
1104	Development and progress of clinical trials of Coronavirus Disease 2019 antiviral drugs. 2020 , 13, 945-956	2
1103	Repurposing approved drugs as potential inhibitors of 3CL-protease of SARS-CoV-2: Virtual screening and structure based drug design. 2020 , 88, 107351	40
1102	The "Infodemic" of COVID-19. 2020 , 72, 1806-1808	18
1101	The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse. 2020 , 9, 561-572	15
1100	Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time. 2020 , 56, 106129	7
1099	Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2. 2021 , 39, 6828-6841	24
1098	Searching for COVID-19 treatments: First, do no harm. 2020 , 77, 1899-1905	2
1097	Impact of Hydroxychloroquine on Antibody Responses to the SARS-CoV-2 Coronavirus. 2020 , 11, 1739	5
1096	The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19. 2020 , 11, 1991	56
1095	Tocilizumab in severe COVID-19. 2020 , 16, 1457-1458	3
1094	Potential Therapeutic Agents and Associated Bioassay Data for COVID-19 and Related Human Coronavirus Infections. 2020 , 3, 813-834	17

1093	Anti-Inflammatory Properties of Drugs Used to Control COVID-19 and their Effects on the Renin-Angiotensin System and Angiotensin-Converting Enzyme-2. 2020 , 23, 259-277	9
1092	Availability and price changes of potential medicines and equipment for the prevention and treatment of COVID-19 among pharmacy and drug stores in Bangladesh; findings and implications. 2020 ,	8
1091	Cancer therapy and treatments during COVID-19 era. 2020 , 77, 100739	19
1090	COVID-19 reveals Brugada pattern in an adolescent patient. 2020 , 30, 1735-1737	5
1089	Effects of gravity and surface tension on steady microbubble propagation in asymmetric bifurcating airways.. 2020 , 32, 072105	9
1088	Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review. 2020 , 15, 350-358	17
1087	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. 2020 , 26, 2181-2189	27
1086	Understanding immunopathological fallout of human coronavirus infections including COVID-19: Will they cross the path of rheumatologists?. 2020 , 23, 998-1008	7
1085	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. 2020 , 7, e737-e745	223
1084	Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study. 2020 , 15, e0237693	84
1083	Potential diagnostics and therapeutic approaches in COVID-19. 2020 , 510, 488-497	25
1082	Chloroquine and hydroxychloroquine for COVID-19: time to close the chapter. 2021 , 97, 676-677	7
1081	Obesity and COVID-19: A Perspective from the European Association for the Study of Obesity on Immunological Perturbations, Therapeutic Challenges, and Opportunities in Obesity. 2020 , 13, 439-452	26
1080	Second Update for Anaesthetists on Clinical Features of COVID-19 Patients and Relevant Management. 2020 , 9,	1
1079	A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review. 2020 , 10,	4
1078	Antimalarials as Antivirals for COVID-19: Believe it or Not!. 2020 , 360, 618-630	14
1077	Antivirals for COVID-19 in Solid Organ Transplant Recipients. 2020 , 7, 1-11	4
1076	No benefit of hydroxychloroquine on SARS-CoV-2 viral load reduction in non-critical hospitalized patients with COVID-19. 2020 , 51, 1765-1769	4

1075	Rheumatic Musculoskeletal Diseases and COVID-19 A Review of the First 6 Months of the Pandemic. 2020 , 7, 562142	11
1074	COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study. 2020 , 56, 106214	53
1073	Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2. 2020 , 11, 2526-2533	98
1072	Coronavirus disease 2019 (COVID-19) in the heart transplant population: a single-centre experience. 2020 , 58, 899-906	12
1071	Moving fast but going slow: coordination challenges for trials of COVID-19 post-exposure prophylaxis. 2020 , 21, 815	1
1070	[German recommendations for treatment of critically ill patients with COVID-19-version 3]. 2020 , 17, 1-12	3
1069	Large-scale use of hydroxychloroquine for COVID-19 confirms safety, if not effectiveness. 2020 , 82, 23-24	
1068	A critical analysis and review of Lancet COVID-19 hydroxychloroquine study. 2020 , 8, 1809236	0
1067	A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals. 2020 , 18, 390	21
1066	Recent Advances in Pathophysiology, Drug Development and Future Perspectives of SARS-CoV-2. 2020 , 8, 580202	19
1065	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. 2020 , 11, 562264	5
1064	Inoculating Against Fake News About COVID-19. 2020 , 11, 566790	113
1063	Molecular Basis of SARS-CoV-2 Infection and Rational Design of Potential Antiviral Agents: Modeling and Simulation Approaches. 2020 , 19, 4291-4315	36
1062	Hypothesis: What is the Best We Can Do with Hydroxychloroquine for COVID-19?. 2020 , 12, 1139-1144	1
1061	The importance of overweight in COVID-19: A retrospective analysis in a single center of Wuhan, China. 2020 , 99, e22766	12
1060	QT interval measurement with portable device during COVID-19 outbreak. 2020 , 30, 100644	2
1059	Hydroxychloroquine for coronavirus: how not to repurpose a drug during a pandemic. 2020 , 50, 1307-1310	2
1058	How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis. 2020 , 10, e044566	4

1057	Tocilizumab use in Kidney Transplant Patients with COVID-19. 2020 , 34, e14072	14
1056	Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients. 2020 , 11, 1124	41
1055	Will Evidence-based Medicine Survive the COVID-19 Pandemic?. 2020 , 17, 1060-1061	4
1054	Impact of Azithromycin and/or Hydroxychloroquine on Hospital Mortality in COVID-19. 2020 , 9,	19
1053	Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir. 2020 , 28, 625-634	12
1052	Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin. 2020 , 40, 469-471	17
1051	COVID-19 in lung transplant recipients: A single center case series from New York City. 2020 , 20, 3072-3080	25
1050	Observational study of azithromycin in hospitalized patients with COVID-19. 2020 , 15, e0238681	14
1049	A Clinical Pathway for Hospitalized Pediatric Patients With Initial SARS-CoV-2 Infection. 2020 , 10, 810-819	
1048	A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges. 2020 , 2, 1-13	26
1047	Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial. 2020 , 75, 3373-3378	53
1046	Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Mathian. 2020 ,	3
1045	Empiric Therapeutic Anticoagulation and Mortality in Critically Ill Patients With Respiratory Failure From SARS-CoV-2: A Retrospective Cohort Study. 2020 , 60, 1411-1415	20
1044	Clinical Experience with COVID-19 at a Specialty Orthopedic Hospital Converted to a Pandemic Overflow Field Hospital. 2020 , 1-7	3
1043	Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis. 2020 , 35, 3308-3314	59
1042	COVID-19-related disease severity in pregnancy. 2020 , 84, e13339	9
1041	HRS/EHRA/APHRS/LAHRs/ACC/AHA worldwide practice update for telehealth and arrhythmia monitoring during and after a pandemic. 2020 , 36, 813	4
1040	Torsade de pointes caused by hydroxychloroquine use in a patient with a severe form of COVID-19. 2020 , 36, 12	1

1039	Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study. 2020 , 2, e689-e697	29
1038	Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults. 2020 , 10, e041437	24
1037	"Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study". 2020 , 203, 105751	321
1036	Medicare expenditures for conventional and biologic disease modifying agents commonly used for treatment of rheumatoid arthritis. 2020 , 50, 822-826	2
1035	Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings. 2020 , 22, 1855-1863	19
1034	A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19. 2020 , 25, 1108-1122	20
1033	Double-Barreled CRISPR Technology as a Novel Treatment Strategy For COVID-19. 2020 , 3, 790-800	14
1032	Treatment Modalities in the Intensive Care Unit for Coronavirus Disease 2019. 2020 , 56, 154-160	
1031	Cardiovascular Complications Associated with COVID-19 and Potential Therapeutic~Strategies. 2020 , 21,	32
1030	Repurposing Immunomodulatory Therapies against Coronavirus Disease 2019 (COVID-19) in the Era of Cardiac Vigilance: A Systematic Review. 2020 , 9,	5
1029	Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. 2020 , 82, 38-47	64
1028	Treatment Armamentarium of COVID-19: Evolving Strategies and Evidence So Far. 2020 , 10, 599-609	3
1027	A Pediatric Infectious Diseases Perspective of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Novel Coronavirus Disease 2019 (COVID-19) in Children. 2020 , 9, 596-608	18
1026	Of Mice and Men: The Coronavirus MHV and Mouse Models as a Translational Approach to Understand SARS-CoV-2. 2020 , 12,	49
1025	Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection. 2020 , 35, 1346-1353	12
1024	COVID-19 und Immunregulation – von grundlegenden und translationalen Aspekten zu klinischen Implikationen. 2020 , 18, 795-809	6
1023	Pathogenesis, clinical manifestations and complications of coronavirus disease 2019 (COVID-19). 2020 , 15, 1287-1305	52
1022	[German recommendations for treatment of critically ill patients with COVID-19-version 3 : S1-guideline]. 2020 , 69, 653-664	9

1021	COVID-19 infection and its deadly cytokine storm in a young obese adult. 2020 , 10, 295-298	1
1020	Coronavirus Interplay With Lipid Rafts and Autophagy Unveils Promising Therapeutic Targets. 2020 , 11, 1821	33
1019	Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?. 2020 , 11, 1969	5
1018	Low-dose radiotherapy for COVID-19 pneumonia treatment: case report, procedure, and literature review. 2020 , 196, 1086-1093	13
1017	Hydroxychloroquine in COVID-19: Potential Mechanism of Action Against SARS-CoV-2. 2020 , 6, 1-9	37
1016	An Ounce of Prevention and a Pound of Cure: Randomized Clinical Trials of Therapeutics Against COVID-19 and an Assessment of Personal Protective Equipment and Distancing. 2020 , 108, 333-336	1
1015	Probiotics and Coronavirus disease 2019: think about the link. 2021 , 126, 1564-1570	10
1014	Dexamethasone in the era of COVID-19: friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes. 2020 , 12, 80	45
1013	Managing rheumatoid arthritis during COVID-19. 2020 , 39, 3237-3244	21
1012	Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection: A case report. 2020 , 99, e21803	9
1011	Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19. 2020 , 13, 1071-1076	22
1010	Electrocardiographic Changes and Arrhythmias in Hospitalized Patients With COVID-19. 2020 , 13, e009023	6
1009	COVID-19 and the young heart: what are we missing?. 2020 , 16, 553-555	1
1008	Available Compounds With Therapeutic Potential Against COVID-19: Antimicrobial Therapies, Supportive Care, and Probable Vaccines. 2020 , 11, 582025	11
1007	Crosstalk between coronavirus disease 2019 and cardiovascular disease and its treatment. 2020 , 7, 3464	9
1006	Analysis of the predictive factors for a critical illness of COVID-19 during treatment - relationship between serum zinc level and critical illness of COVID-19. 2020 , 100, 230-236	33
1005	Convalescent Plasma for the Treatment of Severe COVID-19 Infection in Cancer Patients. 2020 , 9, 8571-8578	28
1004	Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma. 2020 , 26, 100525	39

1003	Challenges in the Management of Sickle Cell Disease During SARS-CoV-2 Pandemic. 2020 , 26, 1076029620955240	
1002	Hydroxychloroquine in COVID-19: The Study Points to Premature Decisions on Efficacy While Bells Ringing for Safety. 2020 , 12, 115-121	1
1001	Methodological Issues and Controversies in COVID-19 Coagulopathy: A Tale of Two Storms. 2020 , 26, 1076029620945398	3
1000	Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future. 2020 , 11, 1205	68
999	Ligand and structure-based virtual screening applied to the SARS-CoV-2 main protease: an repurposing study. 2020 , 12, 1815-1828	51
998	COVID-19 Therapeutic Options Under Investigation. 2020 , 11, 1196	49
997	Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy. 2020 , 9,	10
996	Potentially modifiable factors to reduce severity of COVID-19 in type 2 diabetes. 2020 , 10, 30	2
995	Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. 2020 , 75, 3379-3385	66
994	Efficacy of various treatment modalities for nCOV-2019: A systematic review and meta-analysis. 2020 , 50, e13383	12
993	Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 and SARS-CoV. 2020 , 94,	113
992	Hydroxychloroquine use in COVID-19: is the risk of cardiovascular toxicity justified?. 2020 , 7,	10
991	Clinical Reasoning: Therapeutic considerations in myasthenic crisis due to COVID-19 infection. 2020 , 95, 840-843	4
990	Preparedness and Reorganization of Care for Coronavirus Disease 2019 Patients in a Swiss ICU: Characteristics and Outcomes of 129 Patients. 2020 , 2, e0173	17
989	Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review. 2020 , 7, 2049936120947517	9
988	A Narrative Review of Emerging Therapeutics for COVID-19. 2020 , 4, 745-758	5
987	Modulation of Autophagy by SARS-CoV-2: A Potential Threat for Cardiovascular System. 2020 , 11, 611275	12
986	A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment. 2020 , 10, 22139	41

985	Pharmacotherapy of Acute COVID-19 Infection and Multisystem Inflammatory Syndrome in Children: Current State of Knowledge. 2020 , 33, 177-189	0
984	Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics. 2020 , 10, 589505	43
983	Managing hyperglycemia during the COVID-19 pandemic: Improving outcomes using new technologies in intensive care. 2020 , 8, 2050312120974174	3
982	Autophagy Modulation in Lymphocytes From COVID-19 Patients: New Therapeutic Target in SARS-COV-2 Infection. 2020 , 11, 569849	7
981	Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension. 2020 , 6, 96	50
980	The contribution of the observational research design to COVID-19 research. 2020 , 2, e650-e652	1
979	Ethical Challenges in Clinical Research During the COVID-19 Pandemic. 2020 , 17, 717-722	12
978	COVID-19;The origin, genetics,and management of the infection of mothers and babies. 2020 , 7, 371-388	
977	Rapid Assessment of Proarrhythmic Potential Using Human iPSC-Derived Cardiomyocytes. 2020 , 6, 1860-1862	0
976	COVID-19 Investigational Treatments in Use Among Hospitalized Patients Identified Through the US Coronavirus Disease 2019-Associated Hospitalization Surveillance Network, March 1-June 30, 2020. 2020 , 7, ofaa528	4
975	Inhibition of SARS-CoV-2 Entry into Host Cells Using Small Molecules. 2020 , 13,	12
974	Gender differences in treatment of Coronavirus Disease-2019. 2020 , 90,	5
973	An Unusual Case of COVID-19 Presenting as Acute Psychosis. 2020 , 897190020977721	7
972	Integrative Transcriptome Analyses Empower the Anti-COVID-19 Drug Arsenal. 2020 , 23, 101697	11
971	Low hospitalization rate without severe arrhythmias: a prospective survey on 350 patients early home treated with hydroxychloroquine during COVID-19 pandemic. 2020 , 21, 922-923	2
970	Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping. 2020 , 2020, 9465398	18
969	Challenges for Drug Repurposing in the COVID-19 Pandemic Era. 2020 , 11, 588654	41
968	Coronavirus in human diseases: Mechanisms and advances in clinical treatment. 2020 , 1, 270	11

967	Pharmacotherapy for Hospitalized Patients with COVID-19: Treatment Patterns by Disease Severity. 2020 , 80, 1961-1972		13
966	Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). 2020 , 251, 228-248		473
965	Emerging therapies for COVID-19 pneumonia. 2020 , 29, 633-637		10
964	Pediatric COVID-19: An update on the expanding pandemic. 2020 , 7, 61-63		4
963	Psychopharmacology of COVID-19. 2020 , 61, 411-427		33
962	Lack of efficacy of hydroxychloroquine in covid-19. 2020 , 369, m2018		10
961	Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. 2020 , 395, 1763-1770		1167
960	The Urgency of Care during the Covid-19 Pandemic - Learning as We Go. <i>New England Journal of Medicine</i> , 2020 , 382, 2461-2462	59.2	32
959	Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. 2020 , 323, 2493-2502		749
958	Hydroxychloroquine and azithromycin as a treatment of COVID-19. 2020 , 15, 841-843		6
957	Hydroxychloroquine for Covid-19 - When the pandemic runs faster than research. 2020 , 316, 285-286		1
956	SARS-CoV-2: A comprehensive review from pathogenicity of the virus to clinical consequences. 2020 , 92, 1864-1874		66
955	A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. <i>New England Journal of Medicine</i> , 2020 , 383, 517-525	59.2	803
954	Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces. 2020 , 20, 717-723		11
953	Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: Risks and benefits at the time of COVID-19 pandemic. 2020 , 12, 659-667		19
952	Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. 2020 , 63, 1515-1521		85
951	Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. 2020 , 98, 115094		152
950	COVID-19 treatments, QT interval, and arrhythmic risk: The need for an international registry on arrhythmias. 2020 , 17, 1423-1424		11

949	[COVID-19: Pathogenesis of a multi-faceted disease]. 2020 , 41, 375-389	12
948	Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity. 2020 , 61, 972-982	28
947	The immunology of COVID-19: is immune modulation an option for treatment?. 2020 , 2, e428-e436	139
946	Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. 2020 , 22, 941-956	60
945	An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19). 2020 , 40, 591-601	55
944	Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020. 2020 , 87, 431-437	12
943	Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. 2020 , 7, 1428-1436	48
942	Comment on "Is the type of diabetes treatment relevant to outcome of COVID-19?". 2020 , 12, 705-707	1
941	Evidence of Protective Effect of Hydroxychloroquine on COVID-19. 2020 , 47, 1587	4
940	SARS-CoV-2 COVID-19 susceptibility and lung inflammatory storm by smoking and vaping. 2020 , 17, 21	46
939	The impact of ethnicity on clinical outcomes in COVID-19: A systematic review. 2020 , 23, 100404	296
938	HRS/EHRA/APHRS/LAHRs/ACC/AHA Worldwide Practice Update for Telehealth and Arrhythmia Monitoring During and After a Pandemic. 2020 , 76, 1363-1374	20
937	Hydroxychloroquine/ chloroquine as a treatment choice or prophylaxis for Covid-19 at the primary care level in developing countries: A Primum non Nocere dilemma. 2020 , 415, 116972	2
936	Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine. 2020 , 16, 2260-2266	40
935	Covid-19 and autoimmunity. 2020 , 19, 102597	248
934	HRS/EHRA/APHRS/LAHRs/ACC/AHA worldwide practice update for telehealth and arrhythmia monitoring during and after a pandemic. 2020 , 17, e255-e268	13
933	A compendium answering 150 questions on COVID-19 and SARS-CoV-2. 2020 , 75, 2503-2541	58
932	Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies. 2020 , 14, 809-814	68

931	COVID-19 and hydroxychloroquine: Is the wonder drug failing?. 2020 , 78, 1-3	7
930	Targeting the NLRP3 Inflammasome in Severe COVID-19. 2020 , 11, 1518	185
929	Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19. 2020 , 17, 1144-1153	13
928	A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions. 2020 , 9,	38
927	Considerations for Heart Failure Care During the COVID-19 Pandemic. 2020 , 8, 681-691	51
926	Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19. 2020 , 132, 604-613	19
925	SARS-CoV-2 and COVID-19: From the Bench to the Bedside. 2020 , 100, 1455-1466	75
924	Health and Economy in COVID-19 Era: A Plan for Reconstituting Long-Term Economic Security. 2020 , 8, 235	10
923	Coronavirus disease 2019 in an orthotopic liver transplant recipient living with human immunodeficiency virus. 2020 , 22, e13351	8
922	Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. 2020 , 56, 106044	33
921	Approach to Acute Cardiovascular Complications in COVID-19 Infection. 2020 , 13, e007220	54
920	COVID-19 research: an opinion piece. 2020 , 21, 536-540	3
919	Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19. 2020 , 11, 1606	27
918	The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19. 2020 , 39, 198-216	263
917	Dissecting the interaction between COVID-19 and diabetes mellitus. 2020 , 11, 1104-1114	22
916	Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19. 2020 , 20, 248	78
915	Assessing the risk of seizures with chloroquine or hydroxychloroquine therapy for COVID-19 in persons with epilepsy. 2020 , 165, 106399	4
914	In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19. 2020 , 33, 2104-2114	161

913	Oral Methioninase for Covid-19 Methionine-restriction Therapy. 2020 , 34, 1593-1596	5
912	Ocular Manifestations of COVID-19 (SARS-CoV-2): A Critical Review of Current Literature. 2020 , 34, 1619-1628	29
911	Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. 2020 , 38, 100709	48
910	COVID-19 Digital Health Innovation Policy: A Portal to Alternative Futures in the Making. 2020 , 24, 460-469	39
909	COVID-19 in pancreas transplant recipients. 2020 , 22, e13359	5
908	Recent Understandings Toward Coronavirus Disease 2019 (COVID-19): From Bench to Bedside. 2020 , 8, 476	12
907	Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19. 2020 , 1, 114-127.e3	315
906	Effet bénéfique de l'association hydroxychloroquine/azithromycine dans le traitement des patients âgés atteints de la COVID-19 : résultats d'une étude observationnelle. 2020 , 55, 398-403	2
905	Case 18-2020: A 73-Year-Old Man with Hypoxemic Respiratory Failure and Cardiac Dysfunction. <i>New England Journal of Medicine</i> , 2020 , 382, 2354-2364	59.2 9
904	Need for innovative and timely synthesis of evidence during Covid-19 outbreak. 2020 , 77, 165-166	4
903	COVID-19 and the cardiovascular system: A review of current data, summary of best practices, outline of controversies, and illustrative case reports. 2020 , 226, 174-187	8
902	Drug treatment of coronavirus disease 2019 (COVID-19) in China. 2020 , 883, 173326	15
901	Emerging pharmacotherapy for COVID-19. 2020 , 50, 133-137	3
900	Effects of hydroxychloroquine treatment on QT interval. 2020 , 17, 1930-1935	27
899	Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. 2020 , 97, 396-403	330
898	Investigational Therapies for the Treatment of COVID-19: Updates from Ongoing Clinical Trials. 2020 , 6, 1028-1031	5
897	Hydroxychloroquine and COVID-19 - A narrative review. 2020 , 67, S147-S154	5
896	An observational cohort study of hydroxychloroquine and azithromycin for COVID-19: (Can't Get No) Satisfaction. 2020 , 98, 216-217	14

895	Successful Treatment of Covid-19 Associated Cytokine Release Syndrome with Colchicine. A Case Report and Review of Literature. 2021 , 50, 884-890	9
894	Clinical Trials of Repurposed Antivirals for SARS-CoV-2. 2020 , 64,	26
893	Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients. 2020 , 114, 102511	53
892	Canonical and Noncanonical Autophagy as Potential Targets for COVID-19. 2020 , 9,	34
891	COVID-19 in patients with lung cancer. 2020 , 31, 1386-1396	107
890	Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists. 2020 , 83, 1150-1159	13
889	BCG vaccination policy and preventive chloroquine usage: do they have an impact on COVID-19 pandemic?. 2020 , 11, 516	39
888	Is hydroxychloroquine beneficial for COVID-19 patients?. 2020 , 11, 512	57
887	Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19. 2020 , 18, 1119-1133	16
886	Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations. 2020 , 64,	35
885	Intravenous high-dose vitamin C for the treatment of severe COVID-19: study protocol for a multicentre randomised controlled trial. 2020 , 10, e039519	59
884	Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. 2020 , 324, 782-793	1978
883	Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab. 2020 , 114, 102512	39
882	Psychiatric Aspects of Chloroquine and Hydroxychloroquine Treatment in the Wake of Coronavirus Disease-2019: Psychopharmacological Interactions and Neuropsychiatric Sequelae. 2020 , 61, 597-606	17
881	Severe SARS-CoV-2 infection in critical care. 2020 , 34, 28-37	1
880	COVID-19: From pathogenesis models to the first drug trials. 2020 , 13, 1289-1299	1
879	Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. 2020 , 36, 101791	162
878	Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19. 2020 , 8, 2777-2779.e1	14

877	COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium. 2020 , 20, 3140-3148	165
876	Current therapies under investigation for COVID-19: potential COVID-19 treatments. 2020 , 98, 483-489	3
875	Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes. 2020 , 40, 1353-1360	19
874	COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study. 2020 , 2, e557-e564	69
873	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. 2020 , 16, 659-666	40
872	Care of asymptomatic SARS-CoV-2 positive kidney transplant recipients. 2020 , 33, 1331-1332	4
871	Outbreak of COVID-19: An emerging global pandemic threat. 2020 , 129, 110499	22
870	Prophylactic (hydroxy)chloroquine in COVID-19: Potential relevance for cardiac arrhythmia risk. 2020 , 17, 1480-1486	18
869	A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?. 2020 , 56, 106078	29
868	Kidney transplant patients with SARS-CoV-2 infection: The Brescia Renal COVID task force experience. 2020 , 20, 3019-3029	48
867	Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients. 2020 , 1, 100016	79
866	Response to: 'COVID-19 in patients with rheumatological diseases treated with Anti-TNF' by Brito and 'Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China 'hot spot' versus in US 'hot spot': similarities and differences' by Zhao. 2021 , 80, e64	1
865	The impact of the SARS-CoV-2 infection, with special reference to the hematological setting. 2021 , 93, 223-233	16
864	Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: 'Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?' by Xie. 2021 , 80, e7	4
863	Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection. 2021 , 93, 755-759	24
862	Severe Acute Respiratory Syndrome Coronavirus-2 Cardiovascular Complications: Implications for Cardiothoracic Anesthesiology. 2021 , 35, 932-943	1
861	Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients. 2021 , 80, e75	13
860	Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID-19. 2021 , 93, 409-415	78

859	Response to: Correspondence regarding research letter to the editor by Mathian , 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine" by Nikpour. 2020 ,	28
858	HRS/EHRA/APHRS/LAHRs/ACC/AHA worldwide practice update for telehealth and arrhythmia monitoring during and after a pandemic. 2021 , 23, 313	17
857	Response to: 'Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey' by P... 2020 ,	
856	Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia. 2021 , 102, 110-114	3
855	Impact of hydroxychloroquine on the gestational outcomes of pregnant women with immune system problems that necessitate the use of the drug. 2021 , 47, 570-575	1
854	An overview on the use of antivirals for the treatment of patients with COVID19 disease. 2021 , 30, 45-59	1
853	An overview of antiviral strategies for coronavirus 2 (SARS-CoV-2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine. 2021 , 75, e13825	5
852	Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead. 2021 , 890, 173717	14
851	Hydroxychloroquine for Prevention of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: Challenges to Trial Conduct During the Global Pandemic. 2021 , 72, e844-e847	2
850	Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. 2020 ,	26
849	Harnessing immunotherapy to combat COVID-19: A modern snake oil or silver bullet?. 2021 , 76, 335-345	
848	Late onset infectious complications and safety of tocilizumab in the management of COVID-19. 2021 , 93, 1459-1464	38
847	Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a 'real-life' patient cohort. 2021 , 133, 284-291	22
846	Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection. 2021 , 19, 5-16	15
845	Effectiveness of a On-site Medicalization Program for Nursing Homes With COVID-19 Outbreaks. 2021 , 76, e19-e27	9
844	Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. 2021 , 73, 36-47	34
843	Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy. 2021 , 73, 48-52	5
842	Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells. 2021 , 93, 1403-1408	44

841	Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study. 2021 , 93, 1421-1427	17
840	Comparison of COVID-19 Health Risks With Other Viral Occupational Hazards. 2021 , 51, 37-49	5
839	Successful treatment of 28 patients with coronavirus disease 2019 at a medical center in Taiwan. 2021 , 120, 713-719	2
838	Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection. 2021 , 93, 775-785	11
837	SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen. 2021 , 93, 892-898	40
836	[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)]. 2021 , 45, 104-121	8
835	Descripci3n de 12 pacientes VIH positivos que han padecido la COVID-19 en nuestra 6ea. 2021 , 39, 208-210	78
834	Primed for global coronavirus pandemic: Emerging research and clinical outcome. 2021 , 209, 112862	10
833	Screening for natural and derived bio-active compounds in preclinical and clinical studies: One of the frontlines of fighting the coronaviruses pandemic. 2021 , 85, 153311	25
832	Traditional Chinese herbal medicine at the forefront battle against COVID-19: Clinical experience and scientific basis. 2021 , 80, 153337	47
831	Characteristics of SARS-CoV-2 and COVID-19. 2021 , 19, 141-154	1287
830	External validation of a clinical risk score to predict hospital admission and in-hospital mortality in COVID-19 patients. 2021 , 53, 78-86	16
829	Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis. 2021 , 76, 30-42	70
828	Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection. 2021 , 538, 156-162	4
827	Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing. 2021 , 46, 17-27	14
826	Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia. 2021 , 54, 109-112	6
825	Acute aortoiliac occlusion in a patient with novel coronavirus disease-2019. 2021 , 73, 18-21	6
824	Pathogenesis-directed therapy of 2019 novel coronavirus disease. 2021 , 93, 1320-1342	22

823	Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine. 2021 , 27, 264-268	10
822	Content-Aware Galaxies: Digital Fingerprints of Discussions on Social Media. 2021 , 8, 294-307	2
821	QTc prolongation among hydroxychloroquine sulphate-treated COVID-19 patients: An observational study. 2021 , 75, e13767	5
820	Familiar Dermatologic Drugs as Therapies for COVID-19. 2021 , 112, 118-126	1
819	COVID-19 risk stratification algorithms based on sTREM-1 and IL-6 in emergency department. 2021 , 147, 99-106.e4	23
818	C4 article: Implications of COVID-19 in transplantation. 2021 , 21, 1801-1815	7
817	Review on therapeutic targets for COVID-19: insights from cytokine storm. 2021 , 97, 391-398	11
816	Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19. 2021 , 112, 105087	5
815	Stigma & dirty work: In-group and out-group perceptions of essential service workers during COVID-19. 2021 , 93, 102772	15
814	Repurposing medications. 2021 , 19, 336-340	4
813	Predictors and outcomes of healthcare-associated infections in COVID-19 patients. 2021 , 104, 287-292	28
812	The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options. 2021 , 150, 104673	45
811	Identifying public concerns and reactions during the COVID-19 pandemic on Twitter: A text-mining analysis. 2021 , 38, 145-151	6
810	WGO Guidance for the Care of Patients With COVID-19 and Liver Disease. 2021 , 55, 1-11	19
809	Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. 2021 , 133, 111008	14
808	Re: effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: author's response. 2021 , 27, 920-921	11
807	An effective drug against COVID-19: reality or dream?. 2021 , 15, 505-518	4
806	Drug repurposing for the treatment of COVID-19: Pharmacological aspects and synthetic approaches. 2021 , 106, 104488	14

805	Management of Arrhythmias Associated with COVID-19. 2020 , 23, 2	27
804	Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome. 2021 , 40, 108-125	24
803	Decoding the silent walk of COVID-19: Halting its spread using old bullets. 2021 , 133, 110891	1
802	COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges. 2021 , 11, 731-753	28
801	COVID-19: A review of therapeutic strategies and vaccine candidates. 2021 , 222, 108634	109
800	Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19. 2021 , 146, 110394	20
799	Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. 2021 , 102, 538-543	41
798	Insights into disparities observed with COVID-19. 2021 , 289, 463-473	40
797	Drug repurposing: new strategies for addressing COVID-19 outbreak. 2021 , 19, 689-706	10
796	Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: A pilot observational study. 2021 , 40, 41-46	14
795	Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study. 2021 , 27, 611-617	12
794	The evolving obesity challenge: targeting the vagus nerve and the inflammatory reflex in the response. 2021 , 222, 107794	9
793	Coronavirus 2019: clinical and neuropathological aspects. 2021 , 33, 49-57	2
792	COVID-19: The experience from Iran. 2021 , 39, 23-32	5
791	The virus that shook the world: questions and answers about SARS-CoV-2 and COVID-19. 2021 , 35, 74-102	7
790	Challenges of Shared Decision Making in Older Patients with COVID-19. 2021 , 69, 605-606	1
789	Mitigating arrhythmia risk in Hydroxychloroquine and Azithromycin treated COVID-19 patients using arrhythmia risk management plan. 2021 , 32, 100685	4
788	The SARS-CoV-2 Cytopathic Effect Is Blocked by Lysosome Alkalizing Small Molecules. 2021 , 7, 1389-1408	39

787	Initial Report From a Swedish High-volume Transplant Center After the First Wave of the COVID-19 Pandemic. 2021 , 105, 108-114	29
786	HCQ prophylaxis in COVID-19 did not show any QTc prolongation in Healthcare workers. 2021 , 73, 74-76	0
785	Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the completed trials and to improve ongoing and future randomised trial designs. 2021 , 57, 106222	13
784	Access to data from clinical trials in the COVID-19 crisis: open, flexible, and time-sensitive. 2021 , 130, 143-146	10
783	An early experience on the effect of solid organ transplant status on hospitalized COVID-19 patients. 2021 , 21, 2522-2531	18
782	An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy. 2021 , 103, 599-606	4
781	COVID-19: An Update on the Epidemiological, Clinical, Preventive, and Therapeutic Management of 2019 Novel Coronavirus Disease. 2021 , 44, 128-137	10
780	The Decline of the Experimental Paradigm During the COVID-19 Pandemic: A Template for the Future. 2021 , 134, 166-175	7
779	Evidence-Based Management of the Critically Ill Adult With SARS-CoV-2 Infection. 2021 , 36, 18-41	5
778	Emerging treatment strategies for COVID-19 infection. 2021 , 21, 167-179	81
777	Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. 2021 , 53, 117-134	26
776	COVID-19 in transplant recipients: The Spanish experience. 2021 , 21, 1825-1837	62
775	An enlightening role for cytokine storm in coronavirus infection. 2021 , 222, 108615	19
774	Recent progress of antiviral therapy for coronavirus disease 2019. 2021 , 890, 173646	16
773	Clinical Characteristics, Treatment, and Outcomes of Critically Ill Patients With COVID-19: A Scoping Review. 2021 , 96, 183-202	30
772	Re: Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis' by Fiolet et al. 2021 , 27, 918-919	1
771	Hydroxychloroquine for treatment of nonsevere COVID-19 patients: Systematic review and meta-analysis of controlled clinical trials. 2021 , 93, 1265-1275	8
770	Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study. 2021 , 35, 1121-1133	35

769	COVID-19 after hematopoietic stem cell transplantation: report of two children. 2021 , 56, 713-715	10
768	Patient Characteristics and Outcomes of 11 721 Patients With Coronavirus Disease 2019 (COVID-19) Hospitalized Across the United States. 2021 , 72, e558-e565	61
767	Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis. 2021 , 11, 45-52	22
766	Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports. 2021 , 87, 1432-1442	26
765	The Weight of Evidence From Electrophysiology, Observational, and Cardiovascular End Point Studies Demonstrates the Safety of Azithromycin. 2021 , 14, 106-112	1
764	Hydroxychloroquine early in pregnancy and risk of birth defects. 2021 , 224, 290.e1-290.e22	15
763	Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis. 2021 , 394, 775-782	10
762	Cardiovascular Pathophysiology, Epidemiology, and Treatment Considerations of Coronavirus Disease 2019 (COVID-19): A Review. 2021 , 3, 28-40	3
761	Public Perceptions of Resuming Elective Surgery During the COVID-19 Pandemic. 2021 , 36, 397-402.e2	13
760	Immunopathology of Hyperinflammation in COVID-19. 2021 , 191, 4-17	143
759	Impact of COVID-19 on the Cardiovascular System: A Review of Available Reports. 2021 , 35, 411-425	15
758	Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. 2021 , 10, 34-48	37
757	Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. 2021 , 27, 19-27	144
756	Azithromycin in the treatment of COVID-19: a review. 2021 , 19, 147-163	71
755	Management of SARS-CoV-2 pneumonia. 2021 , 93, 1276-1287	11
754	Lines of Treatment of COVID-19 Infection. 2021 , 91-144	1
753	Involuntary Movements Following Administration of Hydroxychloroquine for COVID-19 Pneumonia. 2021 , 14, 75-77	2
752	COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases. 2021 , 41, 257-273	0

751	The strange case of hydroxychloroquine and COVID-19. 2021,	1
750	Regulation Quinone Reductase 2: From Classical Role in Detoxification to Emerging Role as a Novel Regulator of Cellular Activities. 2021, 649-665	
749	Hydroxychloroquine in the post-COVID-19 era: will this pandemic upset decades of clinical practice?. 2021, 40, 1649-1657	1
748	Pharmacist's Role and Pharmaceutical Care During the COVID-19 Pandemic. 2021, 1318, 605-622	1
747	The role of CD4FoxP3 regulatory T cells in the immunopathogenesis of COVID-19: implications for treatment. 2021, 17, 1507-1520	19
746	Sialylation of host proteins as targetable risk factor for COVID-19 susceptibility and spreading: A hypothesis. 2021, 3, 192-197	0
745	COVID-19 Pandemic in Brazil: History, Characteristics, and Evolution. 2021, 1327, 35-47	
744	The Novel Coronavirus and Inflammation. 2021, 1321, 127-138	3
743	Immune and cellular damage biomarkers to predict COVID-19 mortality in hospitalized patients. 2021, 2, 155-162	2
742	A review on potential of natural products in the management of COVID-19.. 2021, 11, 16711-16735	19
741	A case report on a severely ill COVID-19 patient with rapid clearing of chest infiltrates 43 hours after treatment with multiple modalities. 2021, 11, 33-35	0
740	Evidence for Chloroquine/Hydroxychloroquine in the Treatment of COVID-19. 2021, 25, 441-452	2
739	Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: a propensity score-matched analysis. 2021,	6
738	COVID-19 ARDS: A Multispecialty Assessment of Challenges in Care, Review of Research, and Recommendations. 2021, 37, 179-195	3
737	Predicting the 7th Day Efficacy of Acupoint Application of Chinese Herbs (Xiao Zhong Zhi Tong Tie) in Patients with Diarrhea â A Machine-Learning Model Based on XGBoost Algorithm. 2021,	
736	Detection of SARS-CoV-2 from patient fecal samples by whole genome sequencing. 2021, 13, 7	8
735	Cancer patients with COVID-19: a retrospective study of 51 patients in the district of Piacenza, Northern Italy. 2020, 7, FSO645	12
734	Utilitarian Principlism as a Framework for Crisis Healthcare Ethics. 2021, 33, 45-60	11

733	A alimenta�o coletiva como espa�o de sa�de p�blica: os riscos sanit�rios e os desafios trazidos pela pandemia de Covid-19. 2021 , 25,	1
732	Postoperative COVID-19 Pneumonia following Resection of a Large Thoracic Chondrosarcoma. 2021 , 2021, 8866848	
731	Pathogenesis of Multiple Organ Injury in COVID-19 and Potential Therapeutic Strategies. 2021 , 12, 593223	42
730	A Narrative Review of Pharmacologic Treatments for COVID-19: Safety Considerations and Ototoxicity. 2021 , 131, 1626-1632	10
729	Hydroxychloroquine/Chloroquine as Therapeutics for COVID-19: Truth under the Mystery. 2021 , 17, 1538-1546	12
728	Safety of pharmacological options for the management of COVID-19 in pregnant women: An Indian perspective. 2021 , 32, 3-17	3
727	Repurposing FDA-approved drugs to fight COVID-19 using methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulations. 2021 , 23, 100541	9
726	Routine use of immunosuppressants is associated with mortality in hospitalised patients with COVID-19. 2021 , 12, 2042098620985690	1
725	Adsorption of chloroquine and hydroxychloroquine as potential drugs for SARS-CoV-2 infection on BC3 nanosheets: a DFT study.	5
724	A Bibliometric Network Analysis of Coronavirus during the First Eight Months of COVID-19 in 2020. 2021 , 18,	18
723	First principle simulation of coated hydroxychloroquine on Ag, Au and Pt nanoparticles. 2021 , 11, 2131	8
722	Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study. 2021 , 36, e83	10
721	Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2. 2021 , 17, e1009212	85
720	Systematic review and meta-analysis of efficacy and safety of hydroxychloroquine and chloroquine in the treatment of COVID-19. 2021 , 10, 2126-2139	1
719	The Efficacy and Safety of Hydroxychloroquine in Patients with COVID-19: A Multicenter National Retrospective Cohort. 2021 , 10, 439-455	8
718	Clinical course and challenging management of early COVID-19 infection after heart transplantation: case report of two patients. 2021 , 21, 89	6
717	From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?. 2021 , 28,	11
716	Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots. 2021 , 5, rkaa081	20

715	[Chronic inflammatory bowel diseases: what happens when SARS-CoV-2 occurs? Preliminary results from a study conducted at the Hassan II University Teaching Hospital in Fes, Morocco (a case report)]. 2021 , 38, 382	
714	SARS-CoV 2 Infection (Covid-19) and Cardiovascular Disease in Africa: Health Care and Socio-Economic Implications. 2021 , 16, 18	1
713	Hydroxychloroquine in the treatment of COVID-19 disease: a systematic review and meta-analysis. 2021 , 30,	0
712	Twitter in Brazil: Discourses on China in times of coronavirus. 2021 , 3, 100118	3
711	Influence of colchicine prescription in COVID-19-related hospital admissions: a survival analysis. 2021 , 13, 1759720X211002684	4
710	Cardiac manifestations in pediatric COVID-19. 2021 , 76, e3001	
709	Effect of Threat Control Management Strategies on Number Infected by COVID-19. 2021 , 15-41	1
708	Vaccines, Resource Allocation, and Unproven Treatments. 2021 , 151-174	
707	Risk communication in the fight against COVID-19 in Brazil: A rhetorical analysis. 2021 , 31,	1
706	The Rise and Fall of Hydroxychloroquine for the Treatment and Prevention of COVID-19. 2021 , 104, 35-38	13
705	Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review. 2021 , 76, e2342	3
704	COVID-19 pathogenesis, prognostic factors, and treatment strategy: Urgent recommendations. 2021 , 93, 2694-2704	9
703	Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence. 2021 , 49, 401-410	26
702	SARS-CoV-2 Mediated Endothelial Dysfunction: The Potential Role of Chronic Oxidative Stress. 2020 , 11, 605908	37
701	COVID-19 in Qatar: Ways forward in public health and treatment. 2020 , 2020, 38	0
700	CARDIOVASCULAR DISEASE IN COVID-19 PATIENTS. PART 2.. 2021 , 19, 5-9	1
699	Chloroquine and hydroxychloroquine provoke arrhythmias at concentrations higher than those clinically used to treat COVID-19: A simulation study. 2021 , 14, 1092-1100	4
698	Examination of patient characteristics and hydroxychloroquine use based on the US Food and Drug Administration's recommendation: a cross-sectional analysis in New York. 2021 , 11, e042965	2

697	Coronavirus disease 2019 management. 2021 , 27, 169-175	1
696	Methodological quality of COVID-19 clinical research. 2021 , 12, 943	30
695	Biological activity-based modeling identifies antiviral leads against SARS-CoV-2. 2021 , 39, 747-753	14
694	COVID-19 and the generation of novel scientific knowledge: Evidence-based decisions and data sharing. 2021 , 27, 708-715	3
693	Modalities and Mechanisms of Treatment for Coronavirus Disease 2019. 2020 , 11, 583914	4
692	Cross-sectional observational study of epidemiology of COVID-19 and clinical outcomes of hospitalised patients in North West London during March and April 2020. 2021 , 11, e044384	1
691	Observational Study of Chlorpromazine in Hospitalized Patients with COVID-19. 2021 , 41, 221-233	23
690	COVID-19 and the generation of novel scientific knowledge: Research questions and study designs. 2021 , 27, 694-707	1
689	Intensive care management of patients with COVID-19: a practical approach. 2021 , 11, 36	28
688	Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States. 2021 , 78, 568-577	2
687	The COVID-19 Treatment Landscape: A South African Perspective on a Race Against Time. 2021 , 8, 604087	
686	Association between Functional Inhibitors of Acid Sphingomyelinase and Reduced Risk of Intubation or Death in Individuals Hospitalized for Severe COVID-19: results from an observational multicenter study.	1
685	Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH). 2021 , 22, 1127-1141	3
684	Statistical Opportunities to Accelerate Development for COVID-19 Therapeutics. 1-17	3
683	Impact of hydroxychloroquine on disease progression and ICU admissions in patients with SARS-CoV-2 infection. 2021 , 78, 689-696	3
682	Observational study of haloperidol in hospitalized patients with COVID-19. 2021 , 16, e0247122	24
681	Biases in Evaluating the Safety and Effectiveness of Drugs for the Treatment of COVID-19: Designing Real-World Evidence Studies. 2021 , 190, 1452-1456	9
680	Bepridil is potent against SARS-CoV-2 in vitro. 2021 , 118,	38

679	Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. 2021 , 26, 5199-5212	96
678	Use of Hydroxychloroquine in Patients with COVID-19: A Retrospective Observational Study. 2021 , 22, 62-66	2
677	Hydroxychloroquine in patients with novel coronavirus infection (COVID-19): a case-control study. 2021 , 61, 28-39	
676	Effects of Chloroquine and Hydroxychloroquine on the Cardiovascular System - Limitations for Use in the Treatment of COVID-19. 2021 ,	1
675	Comparison of COVID-19 and influenza characteristics. 2021 , 22, 87-98	4
674	Both Chloroquine and Lopinavir/Ritonavir Are Ineffective for COVID-19 Treatment and Combined Worsen the Pathology: A Single-Center Experience with Severely Ill Patients. 2021 , 2021, 8821318	4
673	Examining reporting and representation of patients with cancer in COVID-19 clinical trials. 2021 , 4, e1355	0
672	Systematic review and meta-analysis of the effectiveness and safety of hydroxychloroquine in treating COVID-19 patients. 2021 , 84, 233-241	17
671	Balancing clinical evidence in the context of a pandemic. 2021 , 39, 270-274	1
670	Association between Psychotropic Medications Functionally Inhibiting Acid Sphingomyelinase and reduced risk of Intubation or Death among Individuals with Mental Disorder and Severe COVID-19: an Observational Study.	5
669	Familiar dermatologic drugs as therapies for COVID-19. 2021 , 112, 118-126	0
668	Real-World Evidence for Assessing Pharmaceutical Treatments in the Context of COVID-19. 2021 , 109, 816-828	3
667	The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness. 2021 , 49, 598-622	16
666	Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial.	10
665	Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials. 2021 , 115, 139-150	10
664	Development of a Physiologically Based Pharmacokinetic Model for Hydroxychloroquine and Its Application in Dose Optimization in Specific COVID-19 Patients. 2020 , 11, 585021	2
663	Association between benzodiazepine receptor agonist use and increased mortality among patients hospitalized for COVID-19: results from an observational study.	1
662	A multicenter analysis of the clinical microbiology and antimicrobial usage in hospitalized patients in the US with or without COVID-19. 2021 , 21, 227	5

661	Modeling the Effect of Population-Wide Vaccination on the Evolution of COVID-19 Epidemic in Canada.	4
660	Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. 2021 , 397, 605-612	117
659	Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis. 2021 , 96, 471-479	71
658	Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19). 2021 , 27, 115-126	7
657	MicroRNAs and Long Non-Coding RNAs as Potential Candidates to Target Specific Motifs of SARS-CoV-2. 2021 , 7,	17
656	Clinical course and risk factors for in-hospital mortality of 205 patients with SARS-CoV-2 pneumonia in Como, Lombardy Region, Italy.	
655	Immunogenicity and Neutralizing Activity Comparison of SARS-CoV-2 Spike Full-Length and Subunit Domain Proteins in Young Adult and Old-Aged Mice. 2021 , 9,	1
654	Prise en charge des patients atteints de maladies rhumatismales pendant la pandémie de COVID-19 : la Société française de rhumatologie répond aux questions fréquentes posées jusqu'au 5 mai 2020. 2021 , 88, 93-100	
653	The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2. 2021 , 213, 113157	15
652	Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity. 2021 , 27, 281-290	8
651	Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients. 2021 , 24, 339-355	1
650	Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain?. 2021 , 35, 101658	2
649	Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis. 2021 , 12, 607408	10
648	Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review. 2021 , 61, 429-460	13
647	Chloroquine may induce endothelial injury through lysosomal dysfunction and oxidative stress. 2021 , 414, 115412	7
646	Repurposing Quinoline and Artemisinin Antimalarials as Therapeutics for SARS-CoV-2: Rationale and Implications. 2021 , 4, 613-623	3
645	Coronavirus Disease 2019 Treatment—T-Cells Hold the Key in Severe Cases. 2021 , 42, 003-005	
644	Development and validation of an LC-MS/MS method for determination of hydroxychloroquine, its two metabolites, and azithromycin in EDTA-treated human plasma. 2021 , 16, e0247356	1

643	Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics. 2021 , 11, 6725	12
642	Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir. 2021 , 14, 365-370	6
641	Analyzing knowledge entities about COVID-19 using entitymetrics. 2021 , 126, 1-19	8
640	Effectiveness and quality analysis of methods in studies for the treatment of COVID-19. 1	
639	Clinical Effect of Traditional Chinese Medicine Shenhuang Granule in Critically Ill Patients with COVID-19: A Single-Centered, Retrospective, Observational Study. 2021 , 31, 380-386	5
638	Management of liver disease patients in different clinical situations during COVID-19 pandemic. 2021 , 11, 21	2
637	The time is now: role of pragmatic clinical trials in guiding response to global pandemics. 2021 , 22, 229	5
636	Renal Manifestations of Covid-19: Physiology and Pathophysiology. 2021 , 10,	9
635	A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2. 2021 , 19, e3001128	25
634	Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial. 2021 , 11, 7282	24
633	Current trends and geographical differences in therapeutic profile and outcomes of COVID-19 among pregnant women - a systematic review and meta-analysis. 2021 , 21, 247	11
632	Una presentaci3n infrecuente de COVID-19, con diarrea como s3ntoma inicial, el primer caso diagnosticado en Cartagena, Colombia.. 2021 , 10, 65-74	
631	Clinical characteristics of older patients with COVID-19: a systematic review of case reports. 2021 , 15, 1-15	3
630	Effects of chloroquine or hydroxychloroquine treatment on non-SARS-CoV2 viral infections: A systematic review of clinical studies. 2021 , 31, e2228	4
629	Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH). 2021 , 45, 104-121	1
628	Global COVID-19 pandemic and reporting behavior - An analysis of the Food and Drug Administration adverse events reporting system. 2021 , 30, 707-715	3
627	Clinical Efficacy of Hydroxychloroquine in Patients with COVID-19: Findings from an Observational Comparative Study in Saudi Arabia. 2021 , 10,	4
626	Does hydroxychloroquine still have any role in the COVID-19 pandemic?. 2021 , 22, 1257-1266	4

625	Coronil, a Tri-Herbal Formulation, Attenuates Spike-Protein-Mediated SARS-CoV-2 Viral Entry into Human Alveolar Epithelial Cells and Pro-Inflammatory Cytokines Production by Inhibiting Spike Protein-ACE-2 Interaction. 2021 , 14, 869-884	11
624	Baseline use of hydroxychloroquine or immunosuppressive drugs and the risk of coronavirus disease 2019. 2021 ,	1
623	4-Aminoquinoline compounds from the Spanish flu to COVID-19. 2021 , 135, 111138	3
622	The Economic, Climate Change and Public Health Edges of the Geopolitics of COVID-19: An Exploratory Bibliometric Analysis.	1
621	Chloroquine-induced Prolonged QT Interval in COVID-19 Patients in Indonesia: Case Series. 2021 , 14, 01-05	0
620	Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19. 2021 , 25, 101549	5
619	Worldwide Survey of COVID-19-Associated Arrhythmias. 2021 , 14, e009458	54
618	Different Therapeutic Strategies to Tackle the Infection Associated with COVID-19.	
617	Inpatient Use of Metformin and Acarbose Is Associated with Reduced Mortality of COVID-19 Patients with Type 2 Diabetes Mellitus. 2021 ,	2
616	Experimental therapies under investigation for COVID-19. 2021 , 11, 187-193	2
615	The Trilogy of SARS-CoV-2 in Pediatrics (Part 1): Acute COVID-19 in Special Populations. 2021 , 26, 220-239	4
614	[Factors associated with the occurrence of acute respiratory distress and death in patients with COVID-19 in Burkina Faso]. 2021 , 38, 240-248	
613	Renal Involvement in COVID-19: A Review of the Literature. 2021 , 14, 895-903	7
612	Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection. 2021 , 115, 235-242	30
611	Comprehensive transcriptomic analysis of COVID-19 blood, lung, and airway. 2021 , 11, 7052	45
610	An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?. 2021 , 12, 632677	28
609	Association of hypertension and incident diabetes in Chinese adults: a retrospective cohort study using propensity-score matching. 2021 , 21, 87	1
608	COVID-19 Treatment Guidelines: Do They Really Reflect Best Medical Practices to Manage the Pandemic?. 2021 , 13, 259-284	12

607	Description of 12 HIV-positive patients who have had the COVID-19 in our area. 2021 , 39, 208-210	
606	Obesity is a Major Risk Factor for Hospitalization in Community-Managed COVID-19 Pneumonia. 2021 , 96, 921-931	4
605	The therapeutic effect and safety of the drugs for COVID-19: A systematic review and meta-analysis. 2021 , 100, e25532	
604	Ten things you need to know about intensive care unit management of mechanically ventilated patients with COVID-19. 2021 , 15, 1293-1302	6
603	Current Advances in Novel SARS-CoV-2 Disease (COVID-19) Treatment and Intervention Strategies. 2021 , 2, 353-358	1
602	Hydroxychloroquine Does Not Increase the Risk of Cardiac Arrhythmia in Common Rheumatic Diseases: A Nationwide Population-Based Cohort Study. 2021 , 12, 631869	1
601	Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor. 2021 , 12, 651403	6
600	Prognostic model to identify and quantify risk factors for mortality among hospitalised patients with COVID-19 in the USA. 2021 , 11, e047121	10
599	Clinical characteristics of hospitalised patients with COVID-19 and the impact on mortality: a single-network, retrospective cohort study from Pennsylvania state. 2021 , 11, e042549	2
598	Randomized placebo-controlled pilot clinical trial on the efficacy of ayurvedic treatment regime on COVID-19 positive patients. 2021 , 84, 153494	21
597	Chloroquine and Hydroxychloroquine for the Prevention and Treatment of COVID-19: A Fiction, Hope or Hype? An Updated Review. 2021 , 17, 371-387	31
596	An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients. 2021 , 11, 9023	21
595	Day-90 survival in critically-ill patients with COVID-19 and hydroxychloroquine: a propensity analysis. 2021 , 9, 524	
594	A Dedicated Veno-Venous Extracorporeal Membrane Oxygenation Unit during a Respiratory Pandemic: Lessons Learned from COVID-19 Part II: Clinical Management. 2021 , 11,	2
593	The Rise and Fall of Hydroxychloroquine and Chloroquine in COVID-19. 2021 , 897190021997399	1
592	Clinical course of COVID-19 disease in immunosuppressed renal transplant patients. 2021 , 51, 428-434	5
591	Repurposing Chloroquine Against Multiple Diseases With Special Attention to SARS-CoV-2 and Associated Toxicity. 2021 , 12, 576093	10
590	Repositioning of histamine H receptor antagonist: Doxepin inhibits viropexis of SARS-CoV-2 Spike pseudovirus by blocking ACE2. 2021 , 896, 173897	20

589	Reply to "The perceived efficacy of hydroxychloroquine in observational studies: the results of the confounding effects of 'goals of care'". 2021 , 57, 106307	
588	Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir. 2021 , 7, 792-802	24
587	Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis. 2021 , 897, 173926	33
586	Quinine Inhibits Infection of Human Cell Lines with SARS-CoV-2. 2021 , 13,	12
585	Spike Protein Targeting "Nano-Glue" that Captures and Promotes SARS-CoV-2 Elimination.	0
584	Revisão Sobre O Uso Da Cloroquina E Da Hidroxicloroquina No Tratamento Dos Pacientes Acometidos Pela Covid-19. 43-64	
583	A review on the clinical trials of repurposing therapeutic drugs, mechanisms and preventive measures against SARS-CoV-2. 2021 ,	
582	Pandemic Perspectives on Medicine and Militarism. 2021 , 11, 252-270	1
581	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. 2021 , 12, 2349	83
580	The time to offer treatments for COVID-19. 2021 , 30, 505-518	9
579	COVID-19 Among Patients With Inflammatory Rheumatic Diseases. 2021 , 12, 651715	6
578	The Progress and Challenges of Convalescent Plasma Therapy for Coronavirus Disease 2019. 2021 , 1, 52-58	
577	Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU. 2021 , 51, 411-420	8
576	Chloroquine: Autophagy inhibitor, antimalarial, bitter taste receptor agonist in fight against COVID-19, a reality check?. 2021 , 897, 173928	8
575	Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial. 2021 , 11, 8059	44
574	The efficacy and safety of hydroxychloroquine (HCQ) in treatment of COVID19 -a systematic review and meta-analysis. 2021 , 39, 159-170	4
573	How Are Emerging Data Translated Into Clinical Practice? A Mixed Methods Investigation of Coronavirus Disease 2019 Institutional Treatment Protocols. 2021 , 8, ofab072	4
572	Ongoing COVID-19 Pandemic: A Concise but Updated Comprehensive Review. 2021 , 78, 1718-1729	6

571	Fast prototyping of a local fuzzy search system for decision support and retraining of hospital staff during pandemic. 2021 , 9, 21	1
570	Role of phytoconstituents in the management of COVID-19. 2021 , 341, 109449	9
569	Review of Pharmacotherapy Tried for Management of the Coronavirus Disease-19. 2021 , 53, 137-143	2
568	Repurposing of the herbal formulations: molecular docking and molecular dynamics simulation studies to validate the efficacy of phytochemicals against SARS-CoV-2 proteins. 2021 , 1-15	6
567	The Rise and Fall of Hydroxychloroquine with the COVID-19 Pandemic: Narrative Review of Selected Data. 2021 , 8, 681-691	2
566	Characteristics, outcomes and global trends of respiratory support in patients hospitalized with COVID-19 pneumonia: a scoping review. 2021 , 87, 915-926	4
565	COVID-19 in Kidney Transplant Patients From a Large UK Transplant Center: Exploring Risk Factors for Disease Severity. 2021 , 53, 1160-1168	7
564	Patients with COVID-19: in the dark-NETs of neutrophils. 2021 , 28, 3125-3139	61
563	Observational Study on 255 Mechanically Ventilated Covid Patients at the Beginning of the USA Pandemic.	3
562	SARS-CoV-2 cell entry and targeted antiviral development. 2021 , 11, 3879-3879	5
561	Risk factors associated with the need for oxygen therapy in patients with COVID-19. 2021 , 100, e25819	0
560	Drug repurposing of dermatologic medications to treat coronavirus disease 2019: Science or fiction?. 2021 , 39, 430-445	1
559	Learning to learn by yourself: Unsupervised meta-learning with self-knowledge distillation for COVID-19 diagnosis from pneumonia cases. 2021 , 36, 4033-4064	3
558	Lung histopathological findings in COVID-19 disease - a systematic review. 2021 , 16, 34	13
557	Molecular docking identification for the efficacy of some zinc complexes with chloroquine and hydroxychloroquine against main protease of COVID-19. 2021 , 1231, 129979	21
556	Adapting for the COVID-19 pandemic in Ecuador, a characterization of hospital strategies and patients. 2021 , 16, e0251295	0
555	Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?. 2021 , 36, 3771-3776	5
554	Antiviral treatment selection for SARS-CoV-2 pneumonia. 2021 , 15, 985-992	1

553	Coronavirus Disease 2019 in Kidney Transplant Recipients: Single-Center Experience and Case-Control Study. 2021 , 53, 1187-1193	4
552	Association of hydroxychloroquine and cardiac arrhythmia in patients with systemic lupus erythematosus: A population-based case control study. 2021 , 16, e0251918	0
551	Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. 2021 , 14, 601-621	29
550	Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines. 2021 , 137, 111330	13
549	Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countries. 2021 , 9, 487-497	61
548	Current Paradigms in COVID-19 Research: Proposed Treatment Strategies, Recent Trends and Future Directions. 2021 , 28, 3173-3192	2
547	Drug Repurposing: A Strategy for Discovering Inhibitors against Emerging Viral Infections. 2021 , 28, 2887-29425	
546	Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel-A Drug Antitarget. 2021 , 8, 645172	1
545	Willingness to participate in COVID-19 vaccine trials; a survey among a population of healthcare workers in Uganda. 2021 , 16, e0251992	5
544	Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update. 2021 , 151, 112106	3
543	Polymeric surfaces with biocidal action: challenges imposed by the SARS-CoV-2, technologies employed, and future perspectives. 2021 , 28, 1	1
542	Predicting QT interval prolongation in patients diagnosed with the 2019 novel coronavirus infection. 2021 , 26, e12853	1
541	Clinical Management of COVID-19: A Review of Pharmacological Treatment Options. 2021 , 14,	10
540	Association of Clinical and Immunological Characteristics With Disease Severity and Outcomes in 211 Patients With COVID-19 in Wuhan, China. 2021 , 11, 667487	7
539	Open science saves lives: lessons from the COVID-19 pandemic. 2021 , 21, 117	35
538	Comprehensive Cardiotoxicity Assessment of COVID-19 Treatments Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. 2021 , 183, 227-239	4
537	Implementation of a pilot teleretinal screening protocol for hydroxychloroquine retinopathy in a Los Angeles County safety net clinic. 2021 , 1357633X211018102	
536	Proarrhythmia assessment in treatment with hydroxychloroquine and azithromycin hospitalized elderly COVID-19 patients - our experience. 2021 , 7,	

535	Hydroxychloroquine and mortality in COVID-19 patients: a systematic review and a meta-analysis of observational studies and randomized controlled trials. 2021 , 115, 456-466	5
534	Predictors associated with clinical improvement of SARS-CoV-2 pneumonia. 2021 , 27, 857-863	1
533	COVID-19 treatment combinations and associations with mortality in a large multi-site healthcare system. 2021 , 16, e0252591	9
532	Machine Learning for Predicting the 3-Year Risk of Incident Diabetes in Chinese Adults. 2021 , 9, 626331	5
531	Clinical outcomes of Covid-19 in patients with rheumatic diseases and the effects of the pandemic on rheumatology outpatient care: A single-centre experience from Turkey. 2021 , 75, e14442	
530	HIV and COVID-19: Lessons From HIV and STI Harm Reduction Strategies. 2021 , 18, 261-270	2
529	Role of Chest CT in COVID-19. 2021 , 11, 30	2
528	Clinical, biological and radiological features, 4-week outcomes and prognostic factors in COVID-19 elderly inpatients. 2021 , 51, 368-373	2
527	Analysis and Forecasting Incidence, Intensive Care Unit Admissions, and Projected Mortality Attributable to COVID-19 in Portugal, the UK, Germany, Italy, and France: Predictions for 4 Weeks Ahead. 2021 , 8,	6
526	Hydroxychloroquine plus standard of care compared with standard of care alone in COVID-19: a meta-analysis of randomized controlled trials. 2021 , 11, 11974	9
525	COVID-19 Pandemic and Virtual Clinics for Diabetes Care. 2021 , 23, S3-S15	0
524	Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021. 2021 , 12, 659577	15
523	Clinical Course and Risk Factors for In-Hospital Mortality of 205 Patients with SARS-CoV-2 Pneumonia in Como, Lombardy Region, Italy. 2021 , 9,	1
522	Concordance between the results of randomized and non-randomized interventional clinical trials assessing the efficacy of drugs for COVID-19: a cross-sectional study. 2021 , 76, 2415-2418	4
521	Insights into SARS-CoV-2 evolution, potential antivirals, and vaccines. 2021 , 558, 1-12	9
520	Hydroxychloroquine (HCQ) decreases the benefit of anti-PD-1 immune checkpoint blockade in tumor immunotherapy. 2021 , 16, e0251731	5
519	Antiviral activity of oleandrin and a defined extract of Nerium oleander against SARS-CoV-2. 2021 , 138, 111457	11
518	Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020. 2021 , 10,	2

517	The nature, cause and consequence of COVID-19 panic among social media users in India. 2021 , 11, 53	5
516	Pharmacoepidemiology, Machine Learning, and COVID-19: An Intent-to-Treat Analysis of Hydroxychloroquine, With or Without Azithromycin, and COVID-19 Outcomes Among Hospitalized US Veterans. 2021 , 190, 2405-2419	4
515	Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. 2021 , 95, 107522	22
514	A review on role of nitrous oxide nanoparticles, potential vaccine targets, drug, health care and artificial intelligence to combat COVID-19. 2021 , 1-8	5
513	Drugs that offer the potential to reduce hospitalization and mortality from SARS-CoV-2 infection: The possible role of the sigma-1 receptor and autophagy. 2021 , 25, 435-449	8
512	Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study. 2021 , 16, e0252388	2
511	Adverse Effects Associated With the Use of Antimalarials During The COVID-19 Pandemic in a Tertiary Care Center in Mexico City. 2021 , 12, 668678	2
510	Rationale for a New Outpatient Drug Therapy Algorithm in COVID-19 Patients Based on the Principle of «Multi-hit» Approach. 2021 , 66, 49-61	0
509	Columbia Open Health Data for COVID-19 Research: Database Analysis (Preprint).	
508	COVID-19 in Solid Organ Transplant Recipients in Spain Throughout 2020: Catching the Wave?. 2021 , 105, 2146-2155	5
507	Comparative effectiveness and safety of 32 pharmacological interventions recommended by guidelines for coronavirus disease 2019: a systematic review and network meta-analysis combining 66 trials. 2021 , 134, 1920-1929	2
506	Safeguarding COVID-19 and cancer management: drug design and therapeutic approach. 1, 77	
505	Computational Chemistry to Repurposing Drugs for the Control of COVID-19. 2021 , 1, 111-128	1
504	Disease-drug and drug-drug interaction in COVID-19: Risk and assessment. 2021 , 139, 111642	19
503	Open-label randomized control trial of hydroxychloroquine in patients with moderate to severe coronavirus disease 2019 infection. 2021 , 77, S305-S311	2
502	Pharmacological management of COVID-19 in type 2 diabetes. 2021 , 35, 107927	7
501	Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting. 2021 , 96, 107636	6
500	COVID-19 and the Challenges of Chemotherapy: The Failure Case of Hydroxychloroquine in the Clinical Treatment of SARS-CoV-2 Infection. 2021 , 2,	

499	Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study. 2021 , 18, e1003660	8
498	The Relationship Between Vitamin D and Infections Including COVID-19: Any Hopes?. 2021 , 14, 3849-3870	9
497	Methodological evaluation of bias in observational coronavirus disease 2019 studies on drug effectiveness. 2021 , 27, 949-957	6
496	Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19. 2021 , 76, 285-295	3
495	Efficacy of Different Types of Therapy for COVID-19: A Comprehensive Review. 2021 , 11,	6
494	Abnormal Liver Biochemistry Tests and Acute Liver Injury in COVID-19 Patients: Current Evidence and Potential Pathogenesis. 2021 , 9,	9
493	Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group. 2021 , 62, 2928-2938	5
492	Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study. 2021 , 18, 142	6
491	Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). 2021 , 10, 1837-1885	10
490	Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity. 2021 , 12, 4117	53
489	Target Groups for a Short Dexamethasone Course among Critically Ill COVID-19 Patients. 2021 , 2021, 5557302	0
488	Maternal exposure to hydroxychloroquine and birth defects. 2021 , 113, 1245-1256	0
487	Mental health and quality of life for people with rheumatoid arthritis or ankylosing spondylitis in Aotearoa New Zealand following the COVID-19 national lockdown. 2021 , 41, 1763-1772	1
486	Antimalarial drugs-are they beneficial in rheumatic and viral diseases?-considerations in COVID-19 pandemic. 2021 , 1	3
485	A new application of mTOR inhibitor drugs as potential therapeutic agents for COVID-19. 2021 ,	2
484	Overlooked Shortcomings of Observational Studies of Interventions in Coronavirus Disease 2019: An Illustrated Review for the Clinician. 2021 , 8, ofab317	5
483	Molecular Insights into COVID-19 Pathophysiology, Immune Pathogenesis, Detection, and Treatment. 2021 , 40, 858-868	
482	High-dose dexamethasone treatment for COVID-19 severe acute respiratory distress syndrome: a retrospective study. 2021 , 16, 1913-1919	4

481	COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. 2021 , 11,	44
480	An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages. 2021 , 96, 107763	14
479	Lessons learnt from hydroxychloroquine/azithromycin in treatment of COVID-19. 2021 ,	3
478	Baricitinib against severe COVID-19: effectiveness and safety in hospitalised pretreated patients. 2021 ,	5
477	Hydroxychloroquine and Azithromycin Combination in The Management of COVID-19 Infection: Safety and Effectiveness Challenges. 2021 ,	
476	Dihydropyridine Calcium Channel Blockers and the Risk of Severe COVID-19. 2021 , 160, 89-93	6
475	Mécanismes possiblement impliqués dans les effets antiviraux de la chloroquine et de l'hydroxychloroquine à l'usage pour le traitement de la COVID-19 ?. 2021 , 33, 237-237	
474	Effectiveness of favipiravir in COVID-19: a live systematic review. 2021 , 40, 2575-2583	12
473	In-depth review of cardiopulmonary support in COVID-19 patients with heart failure. 2021 , 13, 299-309	
472	Deep Learning for Drug Discovery: A Study of Identifying High Efficacy Drug Compounds Using a Cascade Transfer Learning Approach. 2021 , 11, 7772	1
471	Adverse Cardiovascular Effects of Anti-COVID-19 Drugs. 2021 , 12, 699949	7
470	Comparative effectiveness research in COVID-19 using real-world data: methodological considerations. 2021 , 10, 1259-1264	0
469	India and management of COVID-19: A case study on published guidelines. 2021 , 15, 171-179	
468	Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance. 2021 , 58, 106428	2
467	COVID-19 in lung transplant recipients: A single-center experience. 2021 , 23, e13700	2
466	The Evolution of Clinical Knowledge During COVID-19: Towards a Global Learning Health System. 2021 , 30, 176-184	2
465	Cardiovascular Safety of Hydroxychloroquine in US Veterans With Rheumatoid Arthritis. 2021 , 73, 1589-1600	3
464	Remdesivir and Mortality in Patients with COVID-19. 2021 ,	5

463	Hesperidin Is a Potential Inhibitor against SARS-CoV-2 Infection. 2021 , 13,	16
462	Hydroxychloroquine versus hydroxychloroquine-azithromycin combination therapy on QT interval prolongation of COVID-19 patients: a systematic review and meta-analysis. 2021 , 63, 475-480	
461	Effects of Hydroxychloroquine and Azithromycin on iPSC-derived Cardiomyocytes: Considerations for the Treatment of COVID-19 Patients.	1
460	In-depth review of cardiopulmonary support in COVID-19 patients with heart failure. 2021 , 13, 298-308	2
459	Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial. 2021 , 97, 107702	13
458	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. 2021 , 6, 317	17
457	Heterocyclic compounds as antiviral drugs: Synthesis, structure-activity relationship and traditional applications.	1
456	Reducing SARS-CoV-2 pathological protein activity with small molecules. 2021 , 11, 383-397	5
455	New prophylaxis regimen for SARS-CoV-2 infection in health professionals with low doses of hydroxychloroquine and bromhexine: a randomised, double-blind placebo clinical trial (ELEVATE Trial). 2021 , 11, e045190	0
454	Comparative effectiveness of endoscopic versus microscopic transsphenoidal surgery for patients with growth hormone secreting pituitary adenoma: An emulated trial. 2021 , 207, 106781	0
453	A metaresearch study revealed susceptibility of Covid-19 treatment research to white hat bias: first, do no harm. 2021 , 136, 55-63	6
452	Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark. 2021 , 10,	4
451	Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial. 2021 , 27, 1124-1130	18
450	A Nomogram for the Determination of the Necessity of Concurrent Chemotherapy in Patients With Stage II-IVa Nasopharyngeal Carcinoma. 2021 , 11, 640077	1
449	Does hydroxychloroquine reduce mortality in patients with COVID-19? A meta-analysis with trial sequential analysis. 2021 , 75, e14448	0
448	Clinical outcome of patients with COVID-19 Pneumonia treated with corticosteroids and colchicine in Colombia. 2021 , 20, 66	5
447	. 2021 ,	0
446	Antiviral treatment could not provide clinical benefit in management of mild COVID-19: A Retrospective Experience from Field hospital. 2021 , 14, 1206-1211	4

445	A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients. 2021 , 12, 698008	4
444	Antirheumatic Drug Intake Influence on Occurrence of COVID-19 Infection in Ambulatory Patients with Immune-Mediated Inflammatory Diseases: A Cohort Study. 2021 , 8, 1887-1895	2
443	Implementation of documented and written informed consent for clinical trials of communicable diseases: Lessons learned, barriers, solutions, future directions identified during the conduct of a COVID-19 clinical trial. 2021 , 23, 100804	4
442	Therapeutic and protective potential of mesenchymal stem cells, pharmaceutical agents and current vaccines against covid-19. 2021 ,	1
441	Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers. 2021 , 13, eabd5524	12
440	Cardiovascular Involvement in Patients with 2019 Novel Coronavirus Disease.. 2021 , 9, 152-160	2
439	Columbia Open Health Data for COVID-19 Research: Database Analysis. 2021 , 23, e31122	1
438	Inpatient use of metformin and acarbose is associated with reduced mortality of COVID-19 patients with type 2 diabetes mellitus. 2021 , e00301	5
437	Antiviral and antibacterial activity of hand sanitizer and surface disinfectant formulations. 2021 , 609, 121139	0
436	Consensus statement on cardiac electrophysiology practices during the coronavirus disease 2019 (COVID-19) pandemic: From the Indian Heart Rhythm Society. 2021 , 21, 281-290	
435	Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics. 2021 , 12, 752227	5
434	Clinical outcomes of concomitant use of enteral and intravenous sedatives and analgesics in mechanically ventilated patients with COVID-19. 2021 ,	1
433	Kidney injury in COVID-19 patients, drug development and their renal complications: Review study. 2021 , 142, 111966	5
432	The utilization of hydroxychloroquine to reduce the main signs and symptoms of COVID-19 patients, a cross-sectional study. 2021 , 70, 102867	1
431	Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial. 2021 , 99, 107969	8
430	On the importance of physicochemical parameters of copper and aminosilane functionalized mesoporous silica for hydroxychloroquine release. 2021 , 130, 112438	2
429	Synthesis of novel calcium channel blockers with ACE2 inhibition and dual antihypertensive/anti-inflammatory effects: A possible therapeutic tool for COVID-19. 2021 , 116, 105272	4
428	Neural connectome prospectively encodes the risk of post-traumatic stress disorder (PTSD) symptom during the COVID-19 pandemic. 2021 , 15, 100378	3

427	Impact of hydroxychloroquine used as DMARD on SARS-CoV-2 tests and infection evolution in a population of 871 patients with inflammatory rheumatic and musculoskeletal diseases. 2021 , 88, 105226	3
426	Integrated gut virome and bacteriome dynamics in COVID-19 patients. 2021 , 13, 1-21	32
425	Utilisation, Availability and Price Changes of Medicines and Protection Equipment for COVID-19 Among Selected Regions in India: Findings and Implications. 2020 , 11, 582154	17
424	What the HIV Pandemic Experience Can Teach the United States About the COVID-19 Response. 2021 , 86, 1-10	2
423	Antimalarial drugs (and lupus). 2021 , 601-609	
422	The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19. 2021 , 18,	5
421	What happens in Brazil? A pandemic of misinformation that culminates in an endless disease burden. 2020 , 54, e07132020	7
420	Systematic review on role of structure based drug design (SBDD) in the identification of anti-viral leads against SARS-Cov-2. 2021 , 2, 100026	4
419	COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options. 2021 , 10, 93-113	9
418	COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs. 2021 , 16, 281-308	21
417	Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study. 2021 , 21, 72	19
416	Rapid Assessment of the Potential Paucity and Price Increases for Suggested Medicines and Protection Equipment for COVID-19 Across Developing Countries With a Particular Focus on Africa and the Implications. 2020 , 11, 588106	20
415	Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages. 2021 , 31, 272-290	102
414	Pharmacotherapeutics of SARS-CoV-2 Infections. 2021 , 16, 12-37	3
413	Impact of repurposed drugs on the symptomatic COVID-19 patients. 2021 , 14, 24-38	3
412	COVID-19: A Review on the Novel Coronavirus Disease Evolution, Transmission, Detection, Control and Prevention. 2021 , 13,	52
411	Beneficial Effects of Intermediate Dosage of Anticoagulation Treatment on the Prognosis of Hospitalized COVID-19 Patients: The ETHRA Study. 2021 , 35, 653-661	12
410	Hydroxychloroquine and COVID-19: a Rheumatologist's Take on the Lessons Learned. 2021 , 21, 5	4

409	COVID-19: What Do Rheumatologists Need to Know?. 2021 , 23, 5	3
408	Mutations in spike protein and allele variations in ACE2 impact targeted therapy strategies against SARS-CoV-2. 2021 , 42, 170-181	0
407	Looking back, moving forward. 2021 , 167-216	
406	Revised Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency Guidelines on the Treatment of Patients with COVID-19. 2021 , 53, 166-219	11
405	Rationale for azithromycin in COVID-19: an overview of existing evidence. 2021 , 8,	23
404	Management of Patients with SARS-CoV-2 Infection. 2021 , 125-135	
403	Predicting the 7th Day Efficacy of Acupoint Application of Chinese Herbs (Xiao Zhong Zhi Tong Tie) in Patients with Diarrhea ã Machine-Learning Model Based on XGBoost Algorithm. 2021 ,	
402	Hydroxychloroquine in COVID-19: therapeutic promises, current status, and environmental implications. 2021 , 28, 40431-40444	13
401	Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo. 2020 , 94,	1
400	Therapeutic approaches against coronaviruses acute respiratory syndrome. 2021 , 9, e00691	4
399	The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients. 2020 , 15, 1501-1506	18
398	Hospital Length of Stay for Patients with Severe COVID-19: Implications for Remdesivir's Value. 2021 , 5, 129-131	9
397	COVID-19 therapy: What weapons do we bring into battle?. 2020 , 28, 115757	12
396	Review of trials currently testing treatment and prevention of COVID-19. 2020 , 26, 988-998	57
395	Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies. 2020 , 14, 641-648	97
394	Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: Prospective, non-randomized trial. 2020 ,	2
393	QT interval and arrhythmic safety of hydroxychloroquine monotherapy in coronavirus disease 2019. 2020 , 1, 167-172	8
392	Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients. 2020 , 101, 283-289	24

391	Immunomodulatory-based therapy as a potential promising treatment strategy against severe COVID-19 patients: A systematic review. 2020 , 88, 106942	5
390	COVID-19 in clinical practice: A narrative synthesis. 2020 , 50, 639-647	1
389	Chloroquine and hydroxychloroquine in the management of COVID-19: Much kerfuffle but little evidence. 2020 , 75, 363-370	20
388	RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies. 2020 , 135, 106805	34
387	Design and study of the novel coumarin derivatives against SARS-CoV-2 main enzymes. 2020 , 1-16	4
386	Repurposing therapeutic agents against SARS-CoV-2 infection: most promising and neoteric progress. 2021 , 19, 1009-1027	17
385	Natural history of COVID-19 and therapeutic options. 2020 , 16, 1159-1184	41
384	Establishment of a Collection of Blood-Derived Products from COVID-19 Patients for Translational Research: Experience of the LPCE Biobank (Nice, France). 2020 , 18, 517-524	6
383	QTc-interval prolongation and increased risk of sudden cardiac death associated with hydroxychloroquine. 2020 ,	1
382	Decreased serum ACE2 levels in patients with connective tissue diseases. 2021 , 60, 4401-4406	5
381	Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease. 2020 , 99, e23720	14
380	Why G6PD Deficiency Should Be Screened Before COVID-19 Treatment With Hydroxychloroquine?. 2021 , 43, 35-36	0
379	COVID-19 Outcomes Among Solid Organ Transplant Recipients: A Case-control Study. 2021 , 105, 128-137	35
378	Organ Donation and Transplantation During the COVID-19 Pandemic: A Summary of the Spanish Experience. 2021 , 105, 29-36	23
377	COVID-19 in Kidney Transplantation: Epidemiology, Management Considerations, and the Impact on Kidney Transplant Practice. 2020 , 6, e582	11
376	Zinc sulfate in combination with a zinc ionophore may improve outcomes in hospitalized COVID-19 patients. 2020 , 69, 1228-1234	63
375	Arbidol treatment with reduced mortality of adult patients with COVID-19 in Wuhan, China: a retrospective cohort study.	9
374	The Role of Hydroxychloroquine in the Age of COVID-19: A Periodic Systematic Review and Meta-Analysis.	17

373	Review of Current Evidence of Hydroxychloroquine in Pharmacotherapy of COVID-19.	6
372	Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2-Priming Protease TMPRSS2. 2020,	24
371	Hydroxychloroquine in COVID-19: An updated systematic review with meta-analysis.	5
370	The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators. 2020,	34
369	Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients – An Observational Study.	20
368	Bepidil is potent against SARS-CoV-2 In Vitro. 2020,	23
367	Simeprevir potently suppresses SARS-CoV-2 replication and synergizes with remdesivir.	13
366	THE TIME COURSE OF THERAPEUTIC INTERVENTIONS FOR COVID-19.	2
365	Chloroquine, hydroxychloroquine, and COVID-19: systematic review and narrative synthesis of efficacy and safety: Systematic review of (hydroxy)chloroquine efficacy and safety.	1
364	Rethinking antiviral effects for COVID-19 in clinical studies: early initiation is key to successful treatment.	5
363	Multicenter point-prevalence evaluation of the utilization and safety of drug therapies for COVID-19. 2020,	1
362	Impaired glucose metabolism in patients with diabetes, prediabetes and obesity is associated with severe Covid-19.	2
361	Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-COV-2 infection: a retrospective cohort study.	1
360	Hydroxychloroquine inhibits trained immunity – implications for COVID-19.	3
359	COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers. 2020,	5
358	Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France.	17
357	Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection.	4
356	Chloroquine and Hydroxychloroquine for the treatment of COVID-19: A Systematic Review and Meta-analysis.	4

355	Treatment Response to Hydroxychloroquine and Antibiotics for mild to moderate COVID-19: a retrospective cohort study from South Korea.	5
354	Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.	1
353	Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 in vitro infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19.	8
352	Discriminating Mild from Critical COVID-19 by Innate and Adaptive Immune Single-cell Profiling of Bronchoalveolar Lavages.	11
351	Association between SSRI Antidepressant Use and Reduced Risk of Intubation or Death in Hospitalized Patients with Coronavirus Disease 2019: a Multicenter Retrospective Observational Study.	12
350	The competing risk between in-hospital mortality and recovery: A pitfall in COVID-19 survival analysis research.	3
349	Efficacy of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-Analysis.	4
348	Observational Study of Haloperidol in Hospitalized Patients with Covid-19.	5
347	Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial.	82
346	Observational Study of Chlorpromazine in Hospitalized Patients with Covid-19.	3
345	Prophylactic and Therapeutic Inhibition of In Vitro SARS-CoV-2 Replication by Oleandrin. 2020,	7
344	Observational Study of the Efficiency of Treatments in Patients Hospitalized with Covid-19 in Madrid.	5
343	Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2.	8
342	Massive-scale biological activity-based modeling identifies novel antiviral leads against SARS-CoV-2. 2020,	5
341	Nicotine-replacement therapy, as a surrogate of smoking, and the risk of hospitalization with Covid-19 and all-cause mortality: a nationwide, observational cohort study in France.	3
340	Hospital length of stay for severe COVID-19: implications for Remdesivir's value. 2020,	3
339	Open Science Saves Lives: Lessons from the COVID-19 Pandemic.	11
338	Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study.	7

337	Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2. 2020,	11
336	The Effect of Early Hydroxychloroquine-based Therapy in COVID-19 Patients in Ambulatory Care Settings: A Nationwide Prospective Cohort Study.	6
335	Anakinra and Intravenous IgG versus Tocilizumab in the Treatment of COVID-19 Pneumonia.	2
334	Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials.	7
333	Real-world effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru.	3
332	Melatonin is significantly associated with survival of intubated COVID-19 patients. 2020,	23
331	A placebo-controlled double blind trial of hydroxychloroquine in mild-to-moderate COVID-19.	4
330	Association between Hydroxyzine Use and Reduced Mortality in Patients Hospitalized for Coronavirus Disease 2019: Results from a multicenter observational study.	7
329	Dexamethasone use and Mortality in Hospitalized Patients with Coronavirus Disease 2019: a Multicenter Retrospective Observational Study.	6
328	Lung transplantation for pulmonary fibrosis secondary to severe COVID-19. 2020,	5
327	Low dose hydroxychloroquine is associated with lower mortality in COVID-19: a meta-analysis of 26 studies and 44,521 patients.	2
326	COHD-COVID: Columbia Open Health Data for COVID-19 Research.	2
325	Effective post-exposure prophylaxis of Covid-19 is associated with use of hydroxychloroquine: Prospective re-analysis of a public dataset incorporating novel data.	2
324	Azithromycin in Hospitalised Patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.	4
323	SARS-CoV-2 protein ORF3a is pathogenic in and causes phenotypes associated with COVID-19 post-viral syndrome. 2020,	14
322	COVID-SAFER: Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults. 2020, 68, 1636-1646	21
321	Open drug discovery of anti-virals critical for Canada's pandemic strategy. 2020, 5, 1019-1036	1
320	The epidemiological and clinical profile of COVID-19 in children: Moroccan experience of the Cheikh Khalifa University Center. 2020, 35, 57	6

3 ¹⁹	Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. 2020 , 37, 9	8
3 ¹⁸	Hydroxychloroquine prophylaxis and treatment is ineffective in macaque and hamster SARS-CoV-2 disease models. 2020 , 5,	20
3 ¹⁷	Prioritizing clinical research studies during the COVID-19 pandemic: lessons from New York City. 2020 , 130, 4522-4524	3
3 ¹⁶	Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. 2020 , 22, 290	17
3 ¹⁵	A 61-Year-Old Man with SARS-CoV-2 Infection and Venous Thrombosis Presenting with Painful Swelling and Gangrene of the Lower Limb Consistent with Phlegmasia Cerulea Dolens. 2020 , 21, e928342	8
3 ¹⁴	Preprints During the COVID-19 Pandemic: Public Health Emergencies and Medical Literature. 2020 , 15, 634-636	5
3 ¹³	Complexities of diagnosis and management of COVID-19 in autoimmune diseases: Potential benefits and detriments of immunosuppression. 2020 , 8, 3669-3678	3
3 ¹²	The first wave of COVID-19 in Malta; a national cross-sectional study. 2020 , 15, e0239389	8
3 ¹¹	A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19). 2020 , 15, e0242763	40
3 ¹⁰	Clinical outcomes and inflammatory marker levels in patients with Covid-19 and obesity at an inner-city safety net hospital. 2020 , 15, e0243888	3
3 ⁰⁹	Safety and Efficacy of Hydroxychloroquine in COVID-19: A Systematic Review and Meta-Analysis. 2020 , 12, 483-491	6
3 ⁰⁸	Exploring Repurposing Potential of Existing Drugs in the Management of COVID-19 Epidemic: A Critical Review. 2020 , 12, 463-471	4
3 ⁰⁷	Effects of Short-Term Hydroxychloroquine Plus Moxifloxacin Therapy on Corrected QT Interval and Tp-e Interval in Patients With COVID-19. 2020 , 12, 604-611	6
3 ⁰⁶	COVID-19, neutrophil extracellular traps and vascular complications in obstetric practice. 2020 , 48, 985-994	7
3 ⁰⁵	A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2. 2021 , 13, e13105	32
3 ⁰⁴	New Coronaviral Infection: Features of Clinical Course, Capabilities of Diagnostics, Treatment and Prevention in Adults and Children. 2020 , 19, 123-131	21
3 ⁰³	Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020. 2020 , 19, 2630	45
3 ⁰²	COVID-19: therapeutic approaches description and discussion. 2020 , 92, e20200466	6

301	COVID-19 diagnosis in a patient with critical limb ischemia: complications and clinical outcomes. 2020 , 19, e20200071	2
300	[Results of Open-Label non-Randomized Comparative Clinical Trial: "Bromhexine and Spironolactone for Coronavirus Infection requiring hospitalization (BISCUIT)]. 2020 , 60, 4-15	10
299	[Combination therapy at an early stage of the novel coronavirus infection (COVID-19). Case series and design of the clinical trial "Bromhexine and Spironolactone for Coronavirus Infection requiring hospitalization (BISCUIT)". 2020 , 60, 4-15	7
298	Possibilities for correcting hepatotoxic reactions during therapy in patients with COVID-19 (case report). 2020 , 7, 65-72	2
297	Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2-Priming Protease TMPRSS2. 2021 , 6, 55-74	36
296	Ivermectin for COVID-19 Treatment: Clinical Response at Quasi-Threshold Doses Via Hypothesized Alleviation of CD147-Mediated Vascular Occlusion.	11
295	Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications. 2020 , 13, 4673-4695	20
294	COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development. 2020 , 8, 323-353	8
293	COVID-19-like symptoms observed in Chinese tree shrews infected with SARS-CoV-2. 2020 , 41, 517-526	26
292	Resilience and response of the congenital cardiac network in Italy during the COVID-19 pandemic. 2021 , 22, 9-13	4
291	Pharmacological treatment of COVID-19: an update.	1
290	A Case of Breakthrough COVID-19 during Hydroxychloroquine Maintenance. 2020 , 35, e231	4
289	Clinical Course and Outcomes of 3,060 Patients with Coronavirus Disease 2019 in Korea, January-May 2020. 2020 , 35, e280	44
288	Cytotoxicity Evaluation of Chloroquine and Hydroxychloroquine in Multiple Cell Lines and Tissues by Dynamic Imaging System and Physiologically Based Pharmacokinetic Model. 2020 , 11, 574720	8
287	Hydroxychloroquine in COVID-19 Patients: Pros and Cons. 2020 , 11, 597985	13
286	COVID-19-Associated Hyper-Fibrinolysis: Mechanism and Implementations. 2020 , 11, 596057	7
285	Rapid Assessment of Price Instability and Paucity of Medicines and Protection for COVID-19 Across Asia: Findings and Public Health Implications for the Future. 2020 , 8, 585832	32
284	COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far. 2020 , 26,	94

283	Position Statement on the Use of Antiplatelet Agents and Anticoagulants in Patients Infected with the New Coronavirus (COVID-19) - 2020. 2020 , 115, 292-301	1
282	COVID-19 in China: From epidemiology to treatment (Review). 2020 , 20, 223	2
281	Treatment Options for Severe Acute Respiratory Syndrome, Middle East Respiratory Syndrome, and Coronavirus Disease 2019: a Review of Clinical Evidence. 2020 , 52, 317-334	6
280	Clinical Experience with Use of Remdesivir in the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2: a Case Series. 2020 , 52, 369-380	7
279	Ongoing initiatives to improve the prescribing of medicines across sectors and the implications. 2020 , 10, 85	4
278	Publishing in the time of pandemic: Editorial policy of a dermatology journal during COVID-19. 2020 , 86, 337-340	4
277	Therapeutic status of hydroxychloroquine in COVID-19: A review. 2020 , 36, S160-S165	4
276	Systemic manifestations of COVID-19. 2020 , 36, 435-442	7
275	Metformin Use in Diabetes Prior to Hospitalization: Effects on Mortality in Covid-19. 2020 , 26, 1166-1172	15
274	Case Report: COVID-19 Associated Renal Infarction and Ascending Aortic Thrombosis. 2020 , 103, 1989-1992	10
273	Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study. 2020 , 103, 1635-1639	77
272	Pragmatic Recommendations for Therapeutics of Hospitalized COVID-19 Patients in Low- and Middle-Income Countries. 2020 ,	3
271	The Role of Hydroxychloroquine in COVID-19 Treatment: A Systematic Review and Meta-Analysis. 2020 , 49,	7
270	Real-life Management Strategy of COVID-19 Patients in Bangladesh with No Death: An Observational and Cohort Study. 2020 , 10, 31-35	5
269	Current Approaches to COVID-19: Therapy and Prevention. 2020 , 24, 838-846	10
268	Hydroxychloroquine and Coronavirus Disease 2019: A Systematic Review of a Scientific Failure. 2020 , 11,	6
267	Hydroxychloroquine against COVID-19: A critical appraisal of the existing evidence. 2020 , 7, S110-S116	4
266	Myocardial injury determination improves risk stratification and predicts mortality in COVID-19 patients. 2020 , 27, 489-496	26

265	Guidelines for the pharmacological treatment of COVID-19. The task-force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology. 2020 , 32, 166-196	22
264	Icosapent Ethyl - A Successful Treatment for Symptomatic COVID-19 Infection. 2020 , 12, e10211	9
263	Characterization of Critically Ill COVID-19 Patients at a Brooklyn Safety-Net Hospital. 2020 , 12, e9809	13
262	Inhaled and systemic heparin as a repurposed direct antiviral drug for prevention and treatment of COVID-19. 2020 , 20, e218-e221	19
261	COVID-19 Lung Pathogenesis in SARS-CoV-2 Autopsy Cases. 2021 , 12, 735922	8
260	COVID-19 Prevalence and Outcomes among Individuals with Rheumatoid Arthritis and Systemic Lupus Erythematosus Taking Hydroxychloroquine; A Retrospective Analysis. 2021 , 15, 69-76	1
259	Personalized therapy: can it tame the COVID-19 monster?. 2021 , 18, 583-593	1
258	Sepsis of Patients Infected by SARS-CoV-2: Real-World Experience From the International HOPE-COVID-19-Registry and Validation of HOPE Sepsis Score. 2021 , 8, 728102	1
257	Comment to: Intensive support recommendations for critically-ill patients with suspected or confirmed COVID-19 infection. 2020 , 18, eCE5931	2
256	Therapeutic Approach to Coronavirus Disease. 2020 , 67-97	0
255	Neurological Aspects of the COVID-19 Pandemic. 2020 , 15, 13	
254	I. Cloroquina / hidroxiclороquina y azitromicina. Revisi3n narrativa de seguridad. 2020 , 2, 71-82	
253	Effect of various treatment modalities on the novel coronavirus (nCOV-2019) infection in humans: a systematic review & meta-analysis.	
252	Alveolar early progenitors in the aged human lung have increased expression of ACE2 accompanied with genes involved in beta-amyloid clearance: Indication of SARS-CoV-2 also using soluble ACE2 in aged-lungs to enter ACE2-negative cells.	
251	Systematic benefit-risk assessment for the use of chloroquine or hydroxychloroquine as a treatment for COVID-19: Establishing a dynamic framework for rapid decision-making.	
250	COVID-19: Why SOLIDARITY and DisCoVeRy trials may fail to bring informative and timely results.	
249	Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of COVID-19 Spike pseudotype virus.	
248	Covid-19 in Chile. The experience of a Regional reference Center. Preliminary report.	1

- 247 Monitoring the level of infection by COVID-19: an previous experiment to possibility of future application to the C-reactive protein detection by bioelectric signals. 104-122 1
- 246 Hydroxychloroquine plus standard care compared with the standard care alone in COVID-19: a meta-analysis of randomized controlled trials.
- 245 Hydroxychloroquine and mortality risk of patients with COVID-19: a systematic review and meta-analysis of human comparative studies.
- 244 Adapting for the COVID-19 pandemic in Ecuador, a characterization of hospital strategies and patients.
- 243 Effectiveness and Safety of Chloroquine or Hydroxychloroquine as a mono-therapy or in combination with Azithromycin in the treatment of COVID-19 patients: Systematic Review and Meta-Analysis. 0
- 242 Evaluation of the current therapeutic approaches for COVID-19: a meta-analysis.
- 241 ASSOCIATION BETWEEN ETHNICITY AND SEVERE COVID-19 DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. 2
- 240 A pragmatic approach and treatment of coronavirus disease 2019 (COVID-19) in intensive care unit. **2020**, 66, 1157-1163 2
- 239 Outcomes of Persons With COVID-19 in Hospitals With and Without Standard Treatment With (Hydroxy)chloroquine. 2
- 238 Meta-analysis. **2020**, 8, 73-87
- 237 Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for Covid-19 Outpatients in Saudi Arabia.
- 236 The Role of Traditional Knowledge in the COVID-19 Battle.
- 235 Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Hydroxychloroquine in Healthy Volunteers. 2
- 234 Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines. **2020**, 1, 16 2
- 233 COVID-19 Treatment at a Glance. **2020**, 21, 438-445 1
- 232 Outcomes of COVID-19 Patients Hospitalized at Acute Care Services: Real-World Experience in the New York Metropolitan Area During the Early Pandemic Before Initiation of Clinical Trials. **2021**, 29, e88-e96
- 231 Waiting for Godot: A cross sectional survey based analysis of the hydroxychloroquine prophylaxis strategy against COVID-19 in India. **2020**, 9, 1888
- 230 COVID-19: Internationale Kooperation für standardisierte Therapieempfehlungen und Forschungsprioritäten. **2021**, 9, 11-13

229	Covid-19: The Biggest Threat of the 21 Century: In Respectful Memory of the Warriors All Over the World. 2020 , 21, 409-418	2
228	Pharmacodynamics of Remdesivir: How to Improve for COVID-19 Treatment. 2020 , 1, 431-438	1
227	COVID-19 and Acute Respiratory Distress Syndrome. Impact of corticosteroid treatment and predictors of poor outcome. 2021 , 34, 33-43	2
226	Investigating Side Effects of Existing Drugs Used in Covid-19 Treatment. 2020 ,	
225	Therapy of patients with COVID-19: clinical studies and recommendations in different countries. 2020 , 5-12	1
224	Clinical Features and Treatment of Coronavirus Disease-19 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] Infection). 2020 , 31, 155-163	1
223	Drug-drug interactions. 2022 , 241-265	0
222	The COVID-19 Pandemic: Impact on the Nephrology Community in South Africa. 2020 , 2, 77	
221	Treatment of COVID19 with antimalarial medicines: clinical pharmacology analysis. 2020 , 22, 164-174	
220	Immunotherapy for the Post-Infectious Sequela of SARS-CoV-2 Infection. 2020 , 10, 117-120	1
219	Hydroxychloroquine: the story of one drug during the COVID-19 pandemic. 2020 , 123, 74	
218	Coronavirus disease 2019 (COVID-19)-induced pneumonia in an elderly hemodialysis patient with diabetes. 2020 , 53, 567-572	
217	Intensive care management of patients with COVID-19. 2020 , 36, S29-S38	
216	Natural and semisynthetic candidate molecules for COVID-19 prophylaxis and treatment. 2020 , 61, 321-334	1
215	Basic Critical Care for Management of COVID-19 Patients: Position Paper of Indian Society of Critical Care Medicine, Part-I. 2020 , 24, S244-S253	0
214	SARS-Cov-2 Viral Kinetics in Mild COVID-19 Patients Treated with Chloroquine Regimens or Standard of Care. 2021 , 3, 1-14	
213	An Update on Pharmacological Relevance and Chemical Synthesis of Natural Products and Derivatives with Anti SARS-CoV-2 Activity.. 2021 , 6, 11502-11527	3
212	Factors associated with psychiatric admission and subsequent self-harm repetition: a cohort study of high-risk hospital-presenting self-harm. 2021 , 1-9	1

- 211 An Established Th2-Oriented Response to an Alum-Adjuvanted SARS-CoV-2 Subunit Vaccine Is Not Reversible by Sequential Immunization with Nucleic Acid-Adjuvanted Th1-Oriented Subunit Vaccines. **2021**, 9, 3
- 210 Methodological Rigor in COVID-19 Clinical Research âA Systematic Review and Case-Control Analysis. 1
- 209 Collaboration is a Valuable International/Interdisciplinary Directive for Electrophysiology Progress: Novel & Tangible Important Lessons Learned COVID-EP: NOT ILL. **2020**, 1, 2-5
- 208 Ėcuklarda COVID-19 Tedavisi. 9-14
- 207 Comparative Incidence and Outcomes of COVID-19 in Kidney or Kidney-Pancreas Transplant Recipients Versus Kidney or Kidney-Pancreas Waitlisted Patients: A Pilot Study.
- 206 Rationale and prognosis of repurposed drugs with risk stratification of COVID-19 patients requiring Oxygen supplementation: A systematic review and meta-analysis.
- 205 COVID-19 Therapeutics: Making Sense of It All. **2020**, 31, 239-249
- 204 Genetic determinants of COVID-19 drug efficacy revealed by genome-wide CRISPR screens.
- 203 COVID-19 in a Veterans Affairs Hospital at Suffolk County, Long Island, New York. **2021**, 29, e58-e61
- 202 Personalized Prescription of ACEI/ARBs for Hypertensive COVID-19 Patients.
- 201 Comparative efficacy and safety of current drugs against COVID-19: A systematic review and network meta-analysis.
- 200 Anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) potency of Mefloquine as an entry inhibitor in vitro.
- 199 The efficacy and safety of hydroxychloroquine in COVID19 patients : a multicenter national retrospective cohort.
- 198 Characteristics of COVID-19 patients admitted to a tertiary care hospital in Pune, India, and cost-effective predictors of intensive care treatment requirement.
- 197 Investigational Drugs for the COVID 19 Pandemic âA Concise Review. **2020**, 26, S36-S48
- 196 ROMATOLOJİ PERSPEKTİFİNDE COVID-19.
- 195 The Role of Hydroxychloroquine in COVID-19 Treatment: A Systematic Review and Meta-Analysis. **2020**, 1
- 194 In Silico Study of Pacific oyster Antiviral Polypeptides as Potential Inhibitory Compounds for SARS-CoV-2 Main Protease. **2020**, 11, 2

193	Therapeutic options in the treatment of severe acute respiratory syndrome coronavirus 2 in pregnant patient. 2020 , 2, 100224	0
192	Hydroxychloroquine (HCQ) reverses anti-PD-1 immune murine checkpoint blockade: TCF1 as a marker in humans for COVID-19 and HCQ therapy.	
191	NRITLD Protocol for the Management of Patients with COVID-19 Admitted to Hospitals. 2020 , 19, 91-99	5
190	Innovative diagnostic approach and investigation trends in COVID19-A systematic review. 2020 , 24, 421-436	1
189	A Narrative Review of Antiviral Drugs Used for COVID-19 Pharmacotherapy. 2021 , 13, 163-171	1
188	Drug-Drug Interactions in Patients with COVID-19: A Retrospective Study at a Tertiary Care Hospital in Eastern India. 2021 , 16, 163-169	
187	Symptomatic severe acute respiratory syndrome coronavirus 2 reinfection in a lupus patient treated with hydroxychloroquine: a case report. 2021 , 15, 572	1
186	Characteristics of published/registered clinical trials on COVID-19 treatment: A systematic review. 2021 , 29, 449-467	2
185	Off-label use of hydroxychloroquine in COVID-19: analysis of reports of suspected adverse reactions from the Italian National Network of Pharmacovigilance. 2021 ,	1
184	Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review. 2021 , 22, 304	0
183	COVID-19: Update on Its Ocular Involvements, and Complications From Its Treatments and Vaccinations. 2021 , 10,	5
182	Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial. 2021 , 22, 808	4
181	Screening of Severe Acute Respiratory Syndrome Coronavirus 2 RNA-Dependent RNA Polymerase Inhibitors Using Computational Approach. 2021 ,	4
180	COVID-19 Pandemic Between Severity Facts and Prophylaxis. 2021 , 16, 1934578X2110412	1
179	Risk of bias in observational studies using routinely collected data of comparative effectiveness research: a meta-research study. 2021 , 19, 279	2
178	A Narrative Review of Existing Options for COVID-19-Specific Treatments. 2021 , 2021, 8554192	
177	The Use of Meta-analysis in Pharmacoepidemiology. 2021 , 334-354	
176	Efficacy of chloroquine and hydroxychloroquine for the treatment of hospitalized COVID-19 patients: a meta-analysis. 2021 ,	2

175	Photo-mediated and advanced oxidative processes applied for the treatment of effluents with drugs used for the treatment of early COVID-19: Review. 2021 , 6, 100140	0
174	Translational Modeling of Chloroquine and Hydroxychloroquine Dosimetry in Human Airways for Treating Viral Respiratory Infections.. 2022 , 39, 57	0
173	Clinical effectiveness and safety of sofosbuvirâ€elpatasvir as add-on treatment for COVID-19 patients: Study protocol and preliminary data for the randomized controlled trial. 2021 , 10, 294	
172	Medical Treatment in Covid-19: Changes in Post-treatment Laboratory Results and CT Findings.	
171	Naphthoquine: A Potent Broad-Spectrum Anti-Coronavirus Drug In Vitro.. 2022 , 27,	0
170	High-cited favorable studies for COVID-19 treatments ineffective in large trials.	
169	Understanding the activating mechanism of the immune system against COVID-19 by Traditional Indian Medicine: Network pharmacology approach.. 2022 , 129, 275-379	1
168	Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy.. 2022 , 18, 459-472	7
167	Cardiac involvement in cancer patients under chemotherapy and diagnosed with COVID-19: case report and literature review.. 2022 , 41, 45	1
166	A Time-Series Feature-based Recursive Classification Model to Optimize Treatment Strategies for Improving Outcomes and Resource Allocations of COVID-19 Patients.. 2021 , PP,	1
165	COVID-19 Drug Development. 2021 , 32,	3
164	SARS-CoV-2 infections in patients with autoimmune blistering disorders: a case series and retrospective analysis.. 2022 ,	0
163	Hydroxychloroquine/Chloroquine for the Treatment of Hospitalized Patients with COVID-19: An Individual Participant Data Meta-Analysis.. 2022 ,	1
162	Inflammation and mortality in COVID-19 hospitalized patients with and without type 2 diabetes.. 2022 ,	1
161	Hydroxychloroquine/Chloroquine in COVID-19 With Focus on Hospitalized Patients â€A Systematic Review.	0
160	Clinical Characteristics and Outcomes of Patients With COVID-19-Associated Acute Respiratory Distress Syndrome Who Underwent Lung Transplant.. 2022 ,	2
159	Clinical outcomes of immunomodulatory therapies in the management of COVID-19: A tertiary-care experience from Pakistan.. 2022 , 17, e0262608	0
158	The "Invisible Enemy" SARS-CoV-2: Viral Spread and Drug Treatment.. 2022 , 58,	0

157	Changes in QTc interval after hydroxychloroquine therapy in patients with COVID-19 infection: a large, retrospective, multicentre cohort study.. 2022 , 12, e051579	1
156	Pulmonary Delivery of Aerosolized Chloroquine and Hydroxychloroquine to Treat COVID-19: In Vitro Experimentation to Human Dosing Predictions.. 2022 , 24, 33	1
155	Attitudes towards influenza, and COVID-19 vaccines during the COVID-19 pandemic among a representative sample of the Jewish Israeli population.. 2022 , 17, e0255495	0
154	AYUSH-64 as an adjunct to standard care in mild to moderate COVID-19: An open-label randomized controlled trial in Chandigarh, India.. 2022 , 66, 102814	3
153	COVID-19 AND CANCER COMORBIDITY: THERAPEUTIC OPPORTUNITIES AND CHALLENGES (RUSSIAN TRANSLATION). 2021 , 7, 28-70	
152	Cardiometabolic Morbidity and Other Prognostic Factors for Mortality in Adult Hospitalized COVID-19 Patients in North Jakarta, Indonesia.. 2022 , 17, 9	0
151	Prevalence of comorbidities and symptoms stratified by severity of illness amongst adult patients with COVID-19: a systematic review.. 2022 , 7, e5-e23	0
150	Association between benzodiazepine receptor agonist use and mortality in patients hospitalised for COVID-19: a multicentre observational study.. 2022 , 31, e18	0
149	Organoid technology and lung injury mouse models evaluating effects of hydroxychloroquine on lung epithelial regeneration.. 2022 ,	1
148	Antimicrobial agents and torsades de pointes. 2022 , 231-266	
147	Synergistic Adverse Effects of Azithromycin and Hydroxychloroquine on Human Cardiomyocytes at a Clinically Relevant Treatment Duration.. 2022 , 15,	1
146	Stem cell therapy for COVID-19 pneumonia.. 2022 , 3, 6	1
145	New In Silico Insights into the Application of (Hydroxy)Chloroquine with Macrolide Antibiotic Co-Crystals against the SARS-CoV-2 Virus. 2022 , 2, 230-243	0
144	Mechanism of Action of Small-Molecule Agents in Ongoing Clinical Trials for SARS-CoV-2: A Review.. 2022 , 13, 840639	1
143	Clinical Evidence Informing Treatment Guidelines on Repurposed Drugs for Hospitalized Patients During the Early COVID-19 Pandemic: Corticosteroids, Anticoagulants, (Hydroxy)chloroquine.. 2022 , 10, 804404	1
142	In silico analysis of SARS-CoV-2 proteins as targets for clinically available drugs.. 2022 , 12, 5320	2
141	Obesity & COVID-19: mechanistic insights from adipose tissue.. 2022 ,	1
140	COVID-19 Cardiovascular Connection: A Review of Cardiac Manifestations in COVID-19 Infection and Treatment Modalities.. 2022 , 101186	1

139	Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study.. 2022 , 12, 90	4
138	Reduction in risk of death among patients admitted with COVID-19 between first and second epidemic waves in New York City.. 2022 ,	0
137	Can anti-parasitic drugs help control COVID-19?. 2022 ,	1
136	Efficacy and Safety of Ivermectin and Hydroxychloroquine in Patients with Severe COVID-19: A Randomized Controlled Trial.. 2022 , 14, 160-168	3
135	Postoperative Adjuvant Transarterial Chemoembolization Plus Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma: a Multicentre Retrospective Study.. 2022 , 9, 127-140	0
134	Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir.. 2022 , 16, 827-841	1
133	Prognosis and treatment of complications associated with COVID-19: a systematic review and meta-analysis. 2022 , 1,	0
132	Care of the Hepatology Patient in the COVID-19 Era.. 2022 , 1-12	0
131	High-cited favorable studies for COVID-19 treatments ineffective in large trials.. 2022 ,	1
130	THE SCIENTIFICS DISCUSSION OF WORLDWIDE CHALLENGES OF COVID-19 PANDEMIC AND GENERAL DRUG THERAPY APPROACHES TO COMBAT THE COVID-19 DISEASES. 2022 , 01, 39-56	
129	Trial of Early Antiviral Therapies during Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19: a summary of the protocol and analysis plan for a decentralized randomized controlled trial.. 2022 , 23, 273	
128	Factors predicting in-hospital all-cause mortality in COVID 19 patients at the Laquintinie Hospital Douala, Cameroon.. 2022 , 47, 102292	
127	Assessment of Recovery Time, Worsening and Death, among COVID-19 inpatients and outpatients, under treatment with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso.. 2022 ,	0
126	Discovery of potential anti-SARS-CoV-2 drugs based on large-scale screening in vitro and effect evaluation in vivo.. 2021 , 1	2
125	Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases.. 2021 , 13, 1850-1874	1
124	Efficacy and Safety of Anticoagulation Treatment in COVID-19 Patient Subgroups Identified by Clinical-Based Stratification and Unsupervised Machine Learning: A Matched Cohort Study.. 2021 , 8, 786414	0
123	Drug repurposing and other strategies for rapid coronavirus antiviral development: lessons from the early stage of the COVID-19 pandemic. 2021 , 39-68	
122	A Randomized Controlled Trial of Hydroxychloroquine as Prophylaxis for COVID-19 among Health Care Providers. 2021 , 14, 600-604	0

121	Lived experiences of frontline healthcare providers offering maternal and newborn services amidst the novel corona virus disease 19 pandemic in Uganda: A qualitative study. 2021 , 16, e0259835	1
120	Clinical characteristics and outcomes of COVID-19 in kidney transplant recipients. 2021 , 13, 339-355	
119	Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease.. 2022 , 12, 4925	5
118	âEfficacy and Safety of Fixed Combination of Hydroxychloroquine with Azithromycin Versus Hydroxychloroquine and Placebo in Patients with Mild COVID-19: Randomized, double blind, Placebo controlled trialâE	
117	Caring for the Critically Ill Patient with COVID-19. 2022 ,	
116	Impact of home CPAP treated obstructive sleep apnea on COVID-19 outcomes in hospitalized patients.. 2022 ,	1
115	It Takes Two to Tango: How the COVID-19 Vaccination Campaign in Israel Was Framed by the Health Ministry vs. the Television News.. 2022 , 10, 887579	
114	Routine laboratory parameters, including complete blood count, predict COVID-19 in-hospital mortality in geriatric patients.. 2022 , 111674	4
113	Data_Sheet_1.docx. 2020 ,	
112	Data_Sheet_1.docx. 2020 ,	
111	Data_Sheet_2.docx. 2020 ,	
110	Image_1.tif. 2020 ,	
109	Image_2.TIF. 2020 ,	
108	Image_3.TIF. 2020 ,	
107	Image_4.TIF. 2020 ,	
106	Table_1.doc. 2020 ,	
105	Image_1.TIF. 2020 ,	
104	presentation1.pptx. 2020 ,	

103 Table_1.xlsx. 2020,

102	Innovative diagnostic approach and investigation trends in COVID19-A systematic review. 2020, 24, 421	1
101	A narrative review of antiviral drugs used for COVID-19 pharmacotherapy. 2021, 13, 163	2
100	Challenges for the practice of evidence-based medicine during COVID-19 pandemic (practice of evidence-based medicine in the new normal). 2022, 66, 290	0
99	SARS-CoV-2: An Overview of the Genetic Profile and Vaccine Effectiveness of the Five Variants of Concern. 2022, 11, 516	1
98	Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update.. 2022, 109022	2
97	Clinical Characteristics, Risk Factors for Severity and Pharmacotherapy in Hospitalized COVID-19 Patients in the United Arab Emirates.. 2022, 11,	0
96	An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19).. 2022, 27, 38	0
95	Chemistry of polyhalogenated nitrobutadienes, 17: Efficient synthesis of persubstituted chloroquinolinyl-1H-pyrazoles and evaluation of their antimalarial, anti-SARS-CoV-2, antibacterial, and cytotoxic activities. 18, 524-532	1
94	Hydroxychloroquine and Mortality in SARS-Cov-2 Infection; The HOPE- Covid-19 Registry.. 2022, 20,	
93	Efficacy of COVID-19 treatments among geriatric patients: a systematic review. 2022, 9, 204993612210956	0
92	Pharmaceutics Informatics: Bio/Chemoinformatics in Drug Delivery. 2022, 705-724	
91	The effect of intermittent pneumatic compression on deep-vein thrombosis and ventilation-free days in critically ill patients with heart failure. 2022, 12,	0
90	COVID-19: Origin, epidemiology, virology, pathogenesis, and treatment. 2022, 1-17	
89	Outcomes of 2111 COVID-19 Hospitalized Patients Treated with Hydroxychloroquine/Azithromycin and Other Regimens in Marseille, France, 2020: A Monocentric Retrospective Analysis. Volume 18, 603-617	0
88	The Association Between Congestive Heart Failure and One-Year Mortality After Surgery in Singaporean Adults: A Secondary Retrospective Cohort Study Using Propensity-Score Matching, Propensity Adjustment, and Propensity-Based Weighting. 9,	0
87	How to write statistical analysis section in medical research. jim-2022-002479	1
86	COVID-19 tanşyla evde takip edilen hastaların hidroklorokin tedavisine uyumları ve geri bildirimleri.	

- 85 Covid-19: Doctor who sold hydroxychloroquine as "magic bullet" treatment is jailed. o1395
- 84 Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: Prospective, non-randomized trial. **2022**, 40, 289-295
- 83 The Efficiency of Convalescent Plasma Therapy in the Management of Critically Ill Patients Infected With COVID-19: A Matched Cohort Study. 9, 0
- 82 Ethical review of off-label drugs during the COVID-19 pandemic. **2022**, 10, 5541-5550
- 81 Synthesis, crystal structure and in silico studies of novel 2,4-dimethoxy-tetrahydropyrimido[4,5-b]quinolin-6(7H)-ones. **2022**, 12, 18806-18820 4
- 80 Study on Hydroxychloroquinine Sulfate Being Given to the Admitted COVID -19 Positive Patients at Institute of JLNMCH, Bhagalpur, Bihar, India. **2022**,
- 79 Therapeutic Interventions Implemented During the First Year of the COVID-19 Pandemic: A Systematic Review of Evidence. **2022**, 7, 287-302
- 78 Leveraging Real-World Data in COVID-19 Response. 1-33
- 77 COVID-19 in kidney transplant recipients: what have we learned one year later? A cohort study from a tertiary center.
- 76 COVID-19 em receptores de transplante renal: o que aprendemos um ano depois? Um estudo de coorte a partir de um centro terciário.
- 75 Hydroxychloroquine pre-exposure prophylaxis to prevent SARS-CoV-2 among health care workers at risk for SARS-CoV-2 exposure: A nonrandomized controlled trial.
- 74 Mapping Scientific Productivity Trends and Hotspots in Remdesivir Research Publications: A Bibliometric Study from 2016 to 2021. **2022**, 19, 8845 1
- 73 The effect of coronavirus infection on QT and QTc intervals of hospitalized patients in Qazvin, Iran.
- 72 Factors Associated with The Speed and Scope of Diffusion of COVID-19 Therapeutics in a Nationwide Healthcare Setting: A Mixed Methods Investigation.
- 71 Demarcating Patriotic Science on Digital Platforms: Covid-19, Chloroquine and the Institutionalisation of Ignorance in Brazil. 1-25 2
- 70 Azithromycin through the Lens of the COVID-19 Treatment. **2022**, 11, 1063 1
- 69 Subversion of autophagy machinery and organelle-specific autophagy by SARS-CoV-2 and coronaviruses. 0
- 68 Assessment of drugs administered in the Middle East as part of the COVID-19 management protocols. 0

67	Reduction in risk of death among patients admitted with COVID-19 between first and second epidemic waves in New York City.	0
66	Systemic Exposure to Hydroxychloroquine and its relationship with outcome in severely ill COVID-19 patients in New York City.	1
65	Ventricular Tachycardia or Fibrillation Storm in Coronavirus Disease. 2022 , 2022, 1-9	0
64	A nanomaterial targeting the spike protein captures SARS-CoV-2 variants and promotes viral elimination.	3
63	Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine. 2022 , 111, 109161	2
62	Consequences of COVID-19 on the cardiovascular and renal systems. 2022 , 100, 31-38	0
61	The association of antiviral drugs with COVID-19 morbidity: The retrospective analysis of a nationwide COVID-19 cohort. 9,	0
60	Lung Transplantation in Patients With COVID-19-The Early National Experience. 2022 ,	0
59	COVID-19 and Cardiovascular Manifestations. 2022 , 102-136	0
58	A multicenter evaluation of antibacterial use in hospitalized patients through the SARS-Cov-2 pandemic waves.	0
57	Development of SARS-CoV-2 infection in patients with rheumatic conditions on hydroxychloroquine monotherapy vs. patients without rheumatic conditions: a retrospective, propensity-matched cohort study. 2022 ,	0
56	Factors Associated with The Speed and Scope of Diffusion of COVID-19 Therapeutics in a Nationwide Healthcare Setting: A Mixed Methods Investigation.	0
55	COVID-19: imbalanced cell-mediated immune response drives to immunopathology. 1-28	1
54	Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis. 2022 , 17, e0273526	0
53	Ivermectin-Induced Clinical Improvement and Alleviation of Significant Symptoms of COVID-19 Outpatients: A Cross-Sectional Study.	0
52	Characteristics of SARS-CoV-2 Infection in an Actively Monitored Cohort of Patients with Lupus Nephritis. 2022 , 10, 2423	0
51	Recent advances in small-molecular therapeutics for COVID-19.	0
50	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19.	6

49	A cross-sectional study of epidemiological determinants for Covid-19 infection among nurses of a tertiary care hospital. 2022 , 11, 305	0
48	Treatment with COLchicine in hospitalized patients affected by COVID-19: the COLVID-19 trial. 2022 ,	0
47	Tissue- and cell-expression of druggable host proteins provide insights into repurposing drugs for COVID -19.	0
46	Excess maternal mortality in Brazil: Regional inequalities and trajectories during the COVID-19 epidemic. 2022 , 17, e0275333	1
45	The failure of drug repurposing for COVID-19 as an effect of excessive hypothesis testing and weak mechanistic evidence. 2022 , 44,	0
44	Expanding current guidelines for management of COVID-19 focusing on low- and middle-income countries. 2022 , 13,	0
43	Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years. 13,	1
42	Association of estimated glomerular filtration rate and incident pre-diabetes: A secondary 5-year longitudinal cohort study in Chinese people. 13,	0
41	COMPREHENSIVE THERAPEUTIC INTERVENTIONS AGAINST SARS-COV-2: A REVIEW AND PROSPECTIVE. 1-12	0
40	Incidence of QTc interval prolongation in patients treated for covid-19 with Doubase C or Hydroxychloroquine-azithromycin at University Hospital of Kinshasa.	0
39	Who's in the Crowd Matters: Cognitive Factors and Beliefs Predict Misinformation Assessment Accuracy. 2022 , 6, 1-18	0
38	The hydroxychloroquine drug reduction the cytokine and cortisol levels in mice. 2022 ,	0
37	Computational search for potential COVID-19 drugs from ayurvedic medicinal plants to identify potential inhibitors against SARS-CoV-2 targets. 2022 , 19,	1
36	Arzneimittelnutzung unter Pandemiebedingungen. 2022 , 171-187	0
35	Sars-Cov-2 Pandemic From The Ophthalmologist' S Perspective. A Review. 2022 , 78, 217-224	0
34	Lung Transplantation in COVID-19 patients: What we have learned so far. 2022 ,	0
33	Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir. 2022 , 15, 1456	0
32	COVID-19 Infection in Rheumatic Patients on Chronic Antimalarial Drugs: A Systematic Review and Meta-Analysis. 2022 , 11, 6865	0

- 31 Prevalence and characteristics of antibiotic prescription for acute COVID-19 patients in Japan. **2022**, 12, ○
- 30 Viral modulation of lipid rafts and their potential as putative antiviral targets. ○
- 29 Spotlight on 4-substituted quinolines as potential anti-infective agents: Journey beyond chloroquine. ○
- 28 Factors associated with the speed and scope of diffusion of COVID-19 therapeutics in a nationwide healthcare setting: a mixed-methods investigation. **2022**, 20, ○
- 27 Hydroxychloroquine for treatment of non-hospitalized adults with COVID -19: A meta-analysis of individual participant data of randomized trials. ○
- 26 Effectiveness of different treatment regimens on patients with COVID-19, hospitalized in Sanandaj hospitals: a retrospective cohort study. **2023**, 16, 1
- 25 Neural Epidermal Growth Factor-like 1 Protein is a novel target antigen in membranous lupus nephritis of Chinese patients. ○
- 24 COVID-19: Cardiology Perspective. **2023**, 361-388 ○
- 23 Pharmacologic Therapeutics for COVID-19. **2023**, 290-318 ○
- 22 Unit information prior for incorporating real-world evidence into randomized controlled trials. **2023**, 32, 229-241 ○
- 21 Drug Repurposing in COVID-19 and Cancer: How Far Have We Come?. **2023**, 519-528 ○
- 20 Antimalarial drugs. **2023**, 363-396 ○
- 19 Antimalarials and macrolides: a review of off-label pharmacotherapies during the first wave of the SARS-CoV-2 pandemic. 59, ○
- 18 Hydroxychloroquine: Time for Reappraisal of Its Effect in COVID-19 Patients. **2023**, 431-439 ○
- 17 Comprehensive evaluation of six interventions for hospitalized patients with COVID-19: A propensity score matching study. **2023**, 31, 517-525 ○
- 16 Effect of an Immune-Boosting, Antioxidant and Anti-Inflammatory Food Supplement in Hospitalized COVID-19 Patients: A Prospective Randomized Pilot Study. **2023**, 15, 1736 ○
- 15 Association of metabolic syndrome with depression in US adults: A nationwide cross-sectional study using propensity score-based analysis. 11, ○
- 14 Impact of lockdown on cardiovascular disease hospitalizations in a Zero-COVID-19 country. **2023**, 217, 98-104 ○

- 13 Association Between Hypertension and New-Onset Non-Alcoholic Fatty Liver Disease in Chinese Non-Obese People: A Longitudinal Cohort Study. Volume 16, 345-363 1
- 12 An overview on the treatments and prevention against COVID-19. **2023**, 20, 0
- 11 Acute COVID-19 Management in Heart Failure Patients: A Specific Setting Requiring Detailed Inpatient and Outpatient Hospital Care. **2023**, 11, 790 0
- 10 Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine. **2023**, 59, 541 0
- 9 Combination of Steroid and Anticoagulant Therapy to Treat Acute/Subacute Severe Cerebral Venous Thrombosis. 0
- 8 Protein powder supplementation in early pregnancy and the risk of gestational diabetes mellitus: a prospective cohort study. 0
- 7 Psychological and financial impact of the COVID-19 pandemic during the first stages of the pandemic: Brazilian orthodontists' perspective. **2022**, 27, 0
- 6 Virtual and In Vitro Screening of Natural Products Identifies Indole and Benzene Derivatives as Inhibitors of SARS-CoV-2 Main Protease (Mpro). **2023**, 12, 519 0
- 5 A Review of Pathology and Analysis of Approaches to Easing Kidney Disease Impact: Host-Pathogen Communication and Biomedical Visualization Perspective. **2023**, 41-57 0
- 4 COVID-19: Natural History and Spectrum of Disease. **2024**, 72-98 0
- 3 Current Strategies to Combat COVID-19. **2023**, 361-374 0
- 2 Exploring the Link Between Malaria and COVID-19. **2023**, 311-338 0
- 1 Lung transplantation for coronavirus disease 2019 acute respiratory distress syndrome/fibrosis: silver lining of a global pandemic. Publish Ahead of Print, 0